Document:

Exhibit 4.5

 

COMMUNICATIONS SALES & LEASING, INC.
 AND
 CSL CAPITAL, LLC

 

 

INDENTURE

 

DATED AS OF            , 20   

 

 

                     , AS THE TRUSTEE

 

 

TABLE OF CONTENTS

 

	
 
    	
 
    	
Page
    
	
 
    	
 
    
	
ARTICLE I.   DEFINITIONS AND INCORPORATION BY REFERENCE
    	
1
    
	
Section 1.1.
    	
Definitions
    	
1
    
	
Section 1.2.
    	
Other Definitions
    	
5
    
	
Section 1.3.
    	
Incorporation by   Reference of Trust Indenture Act
    	
5
    
	
Section 1.4.
    	
Rules of   Construction
    	
6
    
	
ARTICLE II.   THE SECURITIES
    	
6
    
	
Section 2.1.
    	
Issuable in Series
    	
6
    
	
Section 2.2.
    	
Establishment of Terms   of Series of Securities
    	
7
    
	
Section 2.3.
    	
Execution and   Authentication
    	
9
    
	
Section 2.4.
    	
Registrar and Paying   Agent
    	
10
    
	
Section 2.5.
    	
Paying Agent to Hold   Money in Trust
    	
11
    
	
Section 2.6.
    	
Securityholder Lists
    	
11
    
	
Section 2.7.
    	
Transfer and Exchange
    	
11
    
	
Section 2.8.
    	
Mutilated, Destroyed,   Lost and Stolen Securities
    	
12
    
	
Section 2.9.
    	
Outstanding Securities
    	
12
    
	
Section 2.10.
    	
Treasury Securities
    	
13
    
	
Section 2.11.
    	
Temporary Securities
    	
13
    
	
Section 2.12.
    	
Cancellation
    	
13
    
	
Section 2.13.
    	
Defaulted Interest
    	
13
    
	
Section 2.14.
    	
Global Securities
    	
14
    
	
Section 2.15.
    	
CUSIP Numbers
    	
15
    
	
ARTICLE III.   REDEMPTION
    	
15
    
	
Section 3.1.
    	
Notice to Trustee
    	
15
    
	
Section 3.2.
    	
Selection of Securities   to be Redeemed
    	
15
    
	
Section 3.3.
    	
Notice of Redemption
    	
16
    
	
Section 3.4.
    	
Effect of Notice of   Redemption
    	
16
    
	
Section 3.5.
    	
Deposit of Redemption   Price
    	
17
    
	
Section 3.6.
    	
Securities Redeemed in   Part
    	
17
    
	
ARTICLE IV.   COVENANTS
    	
17
    
	
Section 4.1.
    	
Payment of Principal   and Interest
    	
17
    
	
Section 4.2.
    	
SEC Reports
    	
17
    
	
Section 4.3.
    	
Compliance Certificate
    	
17
    
	
Section 4.4.
    	
Stay, Extension and   Usury Laws
    	
18
    
	
Section 4.5.
    	
Corporate Existence
    	
18
    
	
ARTICLE V.   SUCCESSORS
    	
18
    
	
Section 5.1.
    	
Issuer   May Consolidate on Certain Terms
    	
18
    
	
Section 5.2.
    	
Issuer Successor to be   Substituted
    	
19
    
	
Section 5.3.
    	
A Guarantor   May Consolidate on Certain Terms
    	
19
    
	
Section 5.4.
    	
Guarantor Successor to   be Substituted
    	
20
    
	
ARTICLE VI.   DEFAULTS AND REMEDIES
    	
20
    
	
Section 6.1.
    	
Events of Default
    	
20
    
	
Section 6.2.
    	
Acceleration of   Maturity; Rescission and Annulment
    	
22
    
	
Section 6.3.
    	
Collection of   Indebtedness and Suits for Enforcement by Trustee
    	
23
    
				

 

i

 

	
Section 6.4.
    	
Trustee May File Proofs   of Claim
    	
23
    
	
Section 6.5.
    	
Trustee   May Enforce Claims Without Possession of Securities
    	
24
    
	
Section 6.6.
    	
Application of Money   Collected
    	
24
    
	
Section 6.7.
    	
Limitation on Suits
    	
25
    
	
Section 6.8.
    	
Unconditional Right of   Holders to Receive Principal and Interest
    	
25
    
	
Section 6.9.
    	
Restoration of Rights   and Remedies
    	
25
    
	
Section 6.10.
    	
Rights and Remedies   Cumulative
    	
26
    
	
Section 6.11.
    	
Delay or Omission Not   Waiver
    	
26
    
	
Section 6.12.
    	
Control by Holders
    	
26
    
	
Section 6.13.
    	
Waiver of Past Defaults
    	
26
    
	
Section 6.14.
    	
Undertaking for Costs
    	
27
    
	
ARTICLE VII.   TRUSTEE
    	
27
    
	
Section 7.1.
    	
Duties of Trustee
    	
27
    
	
Section 7.2.
    	
Rights of Trustee
    	
28
    
	
Section 7.3.
    	
Individual Rights of   Trustee
    	
30
    
	
Section 7.4.
    	
Trustee’s Disclaimer
    	
30
    
	
Section 7.5.
    	
Notice of Defaults
    	
30
    
	
Section 7.6.
    	
Reports by Trustee to   Holders
    	
30
    
	
Section 7.7.
    	
Compensation and   Indemnity
    	
30
    
	
Section 7.8.
    	
Replacement of Trustee
    	
31
    
	
Section 7.9.
    	
Successor Trustee by   Merger, Etc.
    	
32
    
	
Section 7.10.
    	
Eligibility;   Disqualification
    	
32
    
	
Section 7.11.
    	
Preferential Collection   of Claims Against Issuers
    	
32
    
	
ARTICLE VIII.   SATISFACTION AND DISCHARGE; DEFEASANCE
    	
33
    
	
Section 8.1.
    	
Satisfaction and   Discharge of Indenture
    	
33
    
	
Section 8.2.
    	
Application of Trust   Funds; Indemnification
    	
34
    
	
Section 8.3.
    	
Legal Defeasance of   Securities of any Series
    	
34
    
	
Section 8.4.
    	
Covenant Defeasance
    	
36
    
	
Section 8.5.
    	
Repayment to Issuers
    	
37
    
	
ARTICLE IX.   AMENDMENTS AND WAIVERS
    	
37
    
	
Section 9.1.
    	
Without Consent of   Holders
    	
37
    
	
Section 9.2.
    	
With Consent of Holders
    	
38
    
	
Section 9.3.
    	
Limitations
    	
39
    
	
Section 9.4.
    	
Compliance with Trust   Indenture Act
    	
40
    
	
Section 9.5.
    	
Revocation and Effect   of Consents
    	
40
    
	
Section 9.6.
    	
Notation on or Exchange   of Securities
    	
40
    
	
Section 9.7.
    	
Trustee Protected
    	
40
    
	
ARTICLE X.   MISCELLANEOUS
    	
41
    
	
Section 10.1.
    	
Trust Indenture Act   Controls
    	
41
    
	
Section 10.2.
    	
Notices
    	
41
    
	
Section 10.3.
    	
Communication by   Holders with Other Holders
    	
42
    
	
Section 10.4.
    	
Certificate and Opinion   as to Conditions Precedent
    	
42
    
	
Section 10.5.
    	
Statements Required in   Certificate or Opinion
    	
42
    
	
Section 10.6.
    	
Rules by Trustee   and Agents
    	
42
    
	
Section 10.7.
    	
Legal Holidays
    	
42
    
	
Section 10.8.
    	
No Recourse Against   Others
    	
43
    

 

ii

 

	
Section 10.9.
    	
Counterparts
    	
43
    
	
Section 10.10.
    	
Governing Law
    	
43
    
	
Section 10.11.
    	
No Adverse Interpretation   of Other Agreements
    	
43
    
	
Section 10.12.
    	
Successors
    	
43
    
	
Section 10.13.
    	
Severability
    	
43
    
	
Section 10.14.
    	
Table of Contents,   Headings, Etc.
    	
44
    
	
Section 10.15.
    	
Securities in a Foreign   Currency
    	
44
    
	
Section 10.16.
    	
Judgment Currency
    	
44
    
	
Section 10.17.
    	
USA Patriot Act
    	
45
    
	
Section 10.18.
    	
Force Majeure
    	
45
    
	
ARTICLE XI.   SINKING FUNDS
    	
45
    
	
Section 11.1.
    	
Applicability of   Article
    	
45
    
	
Section 11.2.
    	
Satisfaction of Sinking   Fund Payments with Securities
    	
46
    
	
Section 11.3.
    	
Redemption of   Securities for Sinking Fund
    	
47
    
	
ARTICLE XII.   GUARANTEES
    	
47
    
	
Section 12.1.
    	
Guarantees
    	
47
    

 

iii

 

COMMUNICATIONS SALES & LEASING, INC.
 CSL CAPITAL, LLC

 

Reconciliation and tie between Trust Indenture Act of 1939 and
 Indenture, dated as of            , 20   

 

	
§ 310(a)(1)
    	
 
    	
7.10
    
	
(a)(2)
    	
 
    	
7.10
    
	
(a)(3)
    	
 
    	
Not Applicable
    
	
(a)(4)
    	
 
    	
Not Applicable
    
	
(a)(5)
    	
 
    	
7.10
    
	
(b)
    	
 
    	
7.10
    
	
§ 311(a)
    	
 
    	
7.11
    
	
(b)
    	
 
    	
7.11
    
	
(c)
    	
 
    	
Not Applicable
    
	
§ 312(a)
    	
 
    	
2.6
    
	
(b)
    	
 
    	
10.3
    
	
(c)
    	
 
    	
10.3
    
	
§ 313(a)
    	
 
    	
7.6
    
	
(b)(1)
    	
 
    	
7.6
    
	
(b)(2)
    	
 
    	
7.6
    
	
(c)(1)
    	
 
    	
7.6
    
	
(d)
    	
 
    	
7.6
    
	
§ 314(a)
    	
 
    	
4.2, 10.5
    
	
(b)
    	
 
    	
Not Applicable
    
	
(c)(1)
    	
 
    	
10.4
    
	
(c)(2)
    	
 
    	
10.4
    
	
(c)(3)
    	
 
    	
Not Applicable
    
	
(d)
    	
 
    	
Not Applicable
    
	
(e)
    	
 
    	
10.5
    
	
(f)
    	
 
    	
Not Applicable
    
	
§ 315(a)
    	
 
    	
7.1
    
	
(b)
    	
 
    	
7.5
    
	
(c)
    	
 
    	
7.1
    
	
(d)
    	
 
    	
7.1
    
	
(e)
    	
 
    	
6.14
    
	
§ 316(a)
    	
 
    	
2.10
    
	
(a)(1)(A)
    	
 
    	
6.12
    
	
(a)(1)(B)
    	
 
    	
6.13
    
	
(b)
    	
 
    	
6.8
    
	
§ 317(a)(1)
    	
 
    	
6.3
    
	
(a)(2)
    	
 
    	
6.4
    
	
(b)
    	
 
    	
2.5
    
	
§ 318(a)
    	
 
    	
10.1
    

 

iv

 

Note:  This reconciliation and tie shall not, for any purpose, be deemed to be part of the Indenture.

 

v

 

Indenture dated as of            , 20   among Communications Sales & Leasing, Inc., a Maryland corporation (the “Company”), CSL Capital, LLC, a Delaware limited liability company (“CSL Capital” and together with the Company, the “Issuers”) and                        (the “Trustee”).

 

Each party agrees as follows for the benefit of the other parties and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture.

 

ARTICLE I.
 DEFINITIONS AND INCORPORATION BY REFERENCE

 

Section 1.1.     Definitions.

 

“Additional Amounts” means any additional amounts which are required hereby or by any Security, under circumstances specified herein or therein, to be paid by the Issuers in respect of certain taxes imposed on Holders specified herein or therein and which are owing to such Holders.

 

“Affiliate” of any specified person means any other person directly or indirectly controlling or controlled by or under common control with such specified person. For the purposes of this definition, “control” (including, with correlative meanings, the terms “controlled by” and “under common control with”), as used with respect to any person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such person, whether through the ownership of voting securities or by agreement or otherwise.

 

“Agent” means any Registrar or Paying Agent.

 

“Board of Directors” means (a) with respect to a corporation, the board of directors of the corporation or any duly authorized committee thereof, (b) with respect to a partnership, the board of directors of the general partner of the partnership, and (c) with respect to any other person, the board or committee of such person serving a similar function.

 

“Board Resolution” means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company or CSL Capital, as the case may be, to have been adopted by the Board of Directors or pursuant to authorization by the Board of Directors and to be in full force and effect on the date of the certificate and delivered to the Trustee.

 

“Business Day” means, for a particular Series, any day except a Saturday, Sunday or a legal holiday in The City of New York on which banking institutions or the Corporate Trust Office are authorized or required by law, regulation or executive order to close.

 

“Capital Stock” means (a) in the case of a corporation, corporate stock; (b) in the case of an association or business entity, any and all shares, interests, participations, rights or other equivalents (however designated and whether or not voting) of corporate stock, including each class of common stock and preferred stock of such person; and (c) in the case of a partnership or limited liability company, partnership or membership interests (whether general or limited).

 

1

 

“Company” means the party named as such above until a successor replaces it and thereafter means the successor.

 

“Corporate Trust Office” means the office of the Trustee at which at any particular time its corporate trust business shall be principally administered.

 

“CSL Capital” means the party named as such above until a successor replaces it and thereafter means the successor.

 

“Default” means any event which is, or after notice or passage of time or both would be, an Event of Default.

 

“Depository” means, with respect to the Securities of any Series issuable or issued in whole or in part in the form of one or more Global Securities, the person designated as Depository for such Series by the Company, which Depository shall be a clearing agency registered under the Exchange Act; and if, at any time, there is more than one such person, “Depository” as used with respect to the Securities of any Series shall mean the Depository with respect to the Securities of such Series.

 

“Discount Security” means any Security that provides for an amount less than the stated principal amount thereof to be due and payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.2.

 

“Dollars” and “$” means the currency of the United States of America.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

“Foreign Currency” means any currency or currency unit issued by a government other than the government of the United States of America, including the Euro.

 

“Foreign Government Obligations” means, with respect to Securities of any Series that are denominated in a Foreign Currency, (a) direct obligations of the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged or (b) obligations of a person controlled or supervised by or acting as an agency or instrumentality of such government the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by such government, which, in either case under clauses (a) or (b), are not callable or redeemable at the option of the issuer thereof.

 

“GAAP” means generally accepted accounting principles in the United States of America set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, as in effect from time to time.

 

“Global Security” or “Global Securities” means a Security or Securities, as the case may be, in the form established pursuant to Section 2.2 evidencing all or part of a Series of Securities,

 

2

 

issued to the Depository for such Series or its nominee, and registered in the name of such Depository or nominee.

 

“Guarantee” means a guarantee of any Securities by a Guarantor as contemplated by Article XII, provided that the term “Guarantee,” when used with respect to any Security or with respect to any Series of Securities means a guarantee of such Security or of such Series of Securities, respectively, by a Guarantor of such Security or such Series of Securities, respectively, as contemplated by Article XII.

 

“Guarantor” means any person that issues a Guarantee of any Security of any Series, either on the date such Security is issued or after such date, in accordance with or pursuant to the terms of this Indenture, provided that, upon the release and discharge of such person from its Guarantee in accordance with or pursuant to this Indenture, such person shall cease to be a Guarantor.

 

“Guarantor Order” means a written order signed in the name of a Guarantor by an Officer thereof.

 

“Holder” or “Securityholder” means a person in whose name a Security is registered on the books of the Registrar.

 

“Indenture” means this Indenture as amended or supplemented, from time to time and shall include the form and terms of particular Series of Securities established as contemplated hereunder.

 

“interest” with respect to any Discount Security which by its terms bears interest only after Maturity, means interest payable after Maturity.

 

“Issuers” means the Company and CSL Capital; provided, however, that if CSL Capital is not an Issuer of Securities of a Series established under Section 2.2, then “Issuers” means the Company with respect to such Securities.

 

“Issuer Order” means a written order signed in the name of each of the Issuers by an Officer or Officers thereof.

 

“Issuer Request” means a written request signed in the name of each of the Issuers by an Officer or Officers thereof.

 

“Maturity,” when used with respect to any Security or installment of principal thereof, means the date on which the principal of such Security or such installment of principal becomes due and payable as therein or herein provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption, notice of option to elect repayment or otherwise.

 

“Officer” means the Chief Executive Officer, the Chief Financial Officer, the President, any Vice-President, the Treasurer, the Secretary, any Assistant Treasurer or any Assistant

 

3

 

Secretary of the Issuers (in the case of an Officer’s Certificate to be delivered by a Guarantor, and in the case of a Guarantor Order, of such Guarantor).

 

“Officer’s Certificate” means a certificate signed on behalf of each of the Issuers by an Officer or Officers.

 

“Opinion of Counsel” means a written opinion of legal counsel who is acceptable to the Trustee.  The counsel may be an employee of or counsel to the Issuers or any Guarantor.

 

“person” means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated organization or government or any agency or political subdivision thereof.

 

“principal” of a Security means the principal of the Security plus, when appropriate, the premium, if any, on, and any Additional Amounts in respect of, the Security.

 

“Responsible Officer” means any officer of the Trustee in its Corporate Trust Office having direct responsibility for the administration of this Indenture and also means, with respect to a particular corporate trust matter, any other officer to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with a particular subject and who shall have direct responsibility for the administration of this Indenture.

 

“SEC” means the Securities and Exchange Commission.

 

“Securities” means the debentures, notes or other debt instruments of the Issuers of any Series authenticated and delivered under this Indenture.

 

“Series” or “Series of Securities” means each series of debentures, notes or other debt instruments of the Issuers created pursuant to Sections 2.1 and 2.2 hereof.

 

“Significant Subsidiary” means any Subsidiary in which the Company has invested at least $50,000,000 in capital.

 

“Stated Maturity” when used with respect to any Security or any installment of principal thereof or interest thereon, means the date specified in such Security as the fixed date on which the principal of such Security or such installment of principal or interest is due and payable.

 

“Subsidiary” means, with respect to any person, (a) any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital Stock or other equity interest entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or one or more of the other subsidiaries of that person (or a combination thereof) and (b) any partnership (i) the sole general partner or managing general partner of which is such person or a subsidiary of such person or (ii) the only general partners of which are such person or of one or more subsidiaries of such person (or any combination thereof).

 

4

 

“TIA” means the Trust Indenture Act of 1939 (15 U.S. Code Sections 77aaa-77bbbb) as in effect on the date of this Indenture; provided, however, that in the event the Trust Indenture Act of 1939 is amended after such date, “TIA” means, to the extent required by any such amendment, the Trust Indenture Act as so amended.

 

“Trustee” means the person named as the “Trustee” in the first paragraph of this instrument until a successor Trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter “Trustee” shall mean each person who is then a Trustee hereunder, and if at any time there is more than one such person, “Trustee” as used with respect to the Securities of any Series shall mean the Trustee with respect to Securities of that Series.

 

“U.S. Government Obligations” means direct obligations of, or obligations guaranteed by, the United States of America, and the payment for which the United States pledges its full faith and credit.

 

Section 1.2.                                 Other Definitions.

 

	
 
    	
 
    	
DEFINED IN
    
	
TERM
    	
 
    	
SECTION
    
	
 
    	
 
    	
 
    
	
“Bankruptcy Law”
    	
 
    	
6.1
    
	
“Custodian”
    	
 
    	
6.1
    
	
“Event of Default”
    	
 
    	
6.1
    
	
“Guarantee”
    	
 
    	
12.1(b)
    
	
“Judgment Currency”
    	
 
    	
10.16
    
	
“Legal Holiday”
    	
 
    	
10.7
    
	
“mandatory sinking fund   payment”
    	
 
    	
11.1
    
	
“Market Exchange Rate”
    	
 
    	
10.15
    
	
“New York Banking Day”
    	
 
    	
10.16
    
	
“optional sinking fund   payment”
    	
 
    	
11.1
    
	
“Paying Agent”
    	
 
    	
2.4
    
	
“Registrar”
    	
 
    	
2.4
    
	
“Required Currency”
    	
 
    	
10.16
    
	
“Service Agent”
    	
 
    	
2.4
    
	
“successor person”
    	
 
    	
5.1
    

 

Section 1.3.                                 Incorporation by Reference of Trust Indenture Act.

 

Whenever this Indenture refers to a provision of the TIA, the provision is incorporated by reference in and made a part of this Indenture.  The following TIA terms used in this Indenture have the following meanings:

 

“Commission” means the SEC.

 

“indenture securities” means the Securities.

 

“indenture security holder” means a Securityholder.

 

5

 

“indenture to be qualified” means this Indenture.

 

“indenture trustee” or “institutional trustee” means the Trustee.

 

“obligors” on the indenture securities means the Issuers (and, if such indenture securities are guaranteed by any Guarantor, each such Guarantor) and any successor obligor upon the Securities.

 

All other terms used in this Indenture that are defined by the TIA, defined by TIA reference to another statute or defined by SEC rule under the TIA and not otherwise defined herein are used herein as so defined.

 

Section 1.4.                                 Rules of Construction.

 

Unless the context otherwise requires:

 

(a)                                 a term has the meaning assigned to it;

 

(b)                                 an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP;

 

(c)                                  “or” is not exclusive;

 

(d)                                 words in the singular include the plural, and in the plural include the singular; and

 

(e)                                  provisions apply to successive events and transactions.

 

ARTICLE II.
 THE SECURITIES

 

Section 2.1.                                 Issuable in Series.

 

The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited. The Securities may be issued in one or more Series. All Securities of a Series shall be identical except as may be set forth or determined in the manner provided in a Board Resolution, supplemental indenture or Officers’ Certificate detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution. In the case of Securities of a Series to be issued from time to time, the Board Resolution, Officers’ Certificate or supplemental indenture detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution may provide for the method by which specified terms (such as interest rate, maturity date, record date or date from which interest shall accrue) are to be determined. Securities may differ between Series in respect of any matters, provided that all Series of Securities shall be equally and ratably entitled to the benefits of the Indenture.

 

6

 

Section 2.2.                                 Establishment of Terms of Series of Securities.

 

At or prior to the issuance of any Securities within a Series, the following shall be established (as to the Series generally, in the case of Subsection 2.2.1 and either as to such Securities within the Series or as to the Series generally in the case of Subsections 2.2.2 through 2.2.25) by or pursuant to a Board Resolution, and set forth or determined in the manner provided in a Board Resolution, supplemental indenture or Officers’ Certificate:

 

2.2.1.                                          the title of the Series (which shall distinguish the Securities of that particular Series from the Securities of any other Series);

 

2.2.2.                                          the price or prices (expressed as a percentage of the principal amount thereof) at which the Securities of the Series will be issued;

 

2.2.3.                                          any limit upon the aggregate principal amount of the Securities of the Series which may be authenticated and delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of the Series pursuant to Section 2.7, 2.8, 2.11, 3.6 or 9.6);

 

2.2.4.                                          the date or dates on which the principal of the Securities of the Series is payable;

 

2.2.5.                                          the rate or rates (which may be fixed or variable) per annum or, if applicable, the method used to determine such rate or rates (including, but not limited to, any commodity, commodity index, stock exchange index or financial index) at which the Securities of the Series shall bear interest, if any, the date or dates from which such interest, if any, shall accrue, the date or dates on which such interest, if any, shall commence and be payable and any regular record date for the interest payable on any interest payment date;

 

2.2.6.                                          the place or places where the principal of, and premium, if any, and interest, if any, on the Securities of the Series shall be payable and the method of such payment, if by wire transfer, mail or other means, and the place or places where the Securities of such Series may be surrendered for registration of transfer or exchange and where notices and demands to or upon the Issuers in respect of the Securities of such Series and this Indenture may be served;

 

2.2.7.                                          if applicable, the period or periods within which, the price or prices at which and the terms and conditions upon which the Securities of the Series may be redeemed, in whole or in part, at the option of the Issuers;

 

2.2.8.                                          the obligation, if any, of the Issuers to redeem or purchase the Securities of the Series pursuant to any sinking fund or analogous provisions or at the option of a Holder thereof and the period or periods within which, the price or prices at which, the currency or currencies in which and the other terms and conditions upon which Securities of the Series shall be redeemed or purchased, in whole or in part, pursuant to such obligation;

 

2.2.9.                                          the dates, if any, on which and the price or prices at which the Securities of the Series will be repurchased by the Issuers at the option of the Holders thereof and other detailed terms and provisions of such repurchase obligations;

 

7

 

2.2.10.                                   if other than denominations of $1,000 and any integral multiple thereof, the denominations in which the Securities of the Series shall be issuable;

 

2.2.11.                                   the forms of the Securities of the Series and whether the Securities will be issuable as Global Securities;

 

2.2.12.                                   if other than the principal amount thereof, the portion of the principal amount of the Securities of the Series that shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.2;

 

2.2.13.                                   the currency of denomination of the Securities of the Series, which may be Dollars or any Foreign Currency;

 

2.2.14.                                   the designation of the currency, currencies or currency units in which payment of the principal of and interest, if any, on the Securities of the Series will be made;

 

2.2.15.                                   if payments of principal of or interest, if any, on the Securities of the Series are to be made in one or more currencies or currency units other than that or those in which such Securities are denominated, the manner in which the exchange rate with respect to such payments will be determined;

 

2.2.16.                                   the manner in which the amounts of payment of principal of or interest, if any, on the Securities of the Series will be determined, if such amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index;

 

2.2.17.                                   the provisions, if any, relating to any security provided for the Securities of the Series or Guarantees;

 

2.2.18.                                   any addition to, change in or deletion from the Events of Default which apply to any Securities of the Series and any change in the right of the Trustee or the requisite Holders of such Securities to declare the principal amount thereof due and payable pursuant to Section 6.2;

 

2.2.19.                                   any addition to, deletion of or change in the covenants set forth in Articles IV or V which applies to Securities of the Series;

 

2.2.20.                                   any depositories, interest rate calculation agents, exchange rate calculation agents or other agents with respect to Securities of such Series if other than those appointed herein;

 

2.2.21.                                   the provisions, if any, relating to conversion or exchange of any Securities of such Series, including if applicable, the conversion or exchange price, the conversion or exchange period, the securities or other property into which the Securities will be convertible, provisions as to whether conversion or exchange will be mandatory, at the option of the Holders thereof or at the option of the Issuers, the events requiring an adjustment of the conversion price or exchange price and provisions affecting conversion or exchange if such Series of Securities are redeemed;

 

8

 

2.2.22.                                   whether the Securities of such Series will be senior debt securities or subordinated debt securities and, if applicable, the subordination terms thereof;

 

2.2.23.                                   whether the Securities of such Series are entitled to the benefits of Guarantees pursuant to this Indenture, the terms of such Guarantees, including whether the provisions of Article XII of this Indenture shall apply to such Guarantees, and whether any such Guarantees shall be made on a senior or subordinated basis and, if applicable, the subordination terms of any such Guarantees;

 

2.2.24.                                   whether CSL Capital will act as an Issuer of the Securities of such Series; and

 

2.2.25.                                   any other terms of the Securities of such Series (which may supplement, modify or delete any provision of this Indenture insofar as it applies to such Series or any Guarantees of any Securities of such Series).

 

All Securities of any one Series need not be issued at the same time and may be issued from time to time, consistent with the terms of this Indenture, if so provided by or pursuant to the Board Resolution, supplemental indenture hereto or Officers’ Certificate referred to above.

 

Section 2.3.                                 Execution and Authentication.

 

Any Officer shall sign the Securities for the Issuers by manual or facsimile signature.

 

If an Officer whose signature is on a Security no longer holds that office at the time the Security is authenticated, the Security shall nevertheless be valid.

 

A Security shall not be valid until authenticated by the manual or facsimile signature of the Trustee or an authenticating agent. The signature shall be conclusive evidence that the Security has been authenticated under this Indenture.

 

The Trustee shall at any time, and from time to time, authenticate Securities for original issue in the principal amount provided in the Board Resolution, supplemental indenture hereto or Officers’ Certificate, upon receipt by the Trustee of an Issuer Order. Such Issuer Order may authorize authentication and delivery pursuant to electronic instructions from the Issuers or their duly authorized agent or agents. Each Security shall be dated the date of its authentication unless otherwise provided by a Board Resolution, a supplemental indenture hereto or an Officers’ Certificate.

 

The aggregate principal amount of Securities of any Series outstanding at any time may not exceed any limit upon the maximum principal amount for such Series set forth in the Board Resolution, supplemental indenture hereto or Officers’ Certificate delivered pursuant to Section 2.2, except as provided in Section 2.8.

 

Prior to the issuance of Securities of any Series, the Trustee shall have received and (subject to Section 7.2) shall be fully protected in relying on: (a) the Board Resolution, supplemental indenture hereto or Officers’ Certificate establishing the form of the Securities of that Series or of Securities within that Series and the terms of the Securities of that Series or of

 

9

 

Securities within that Series, (b) an Officers’ Certificate complying with Section 10.4, and (c) an Opinion of Counsel complying with Section 10.4.

 

The Trustee shall have the right to decline to authenticate and deliver any Securities of such Series: (a) if the Trustee, being advised by counsel, determines that such action may not be taken lawfully; or (b) if the Trustee in good faith by its board of directors or trustees, executive committee or a trust committee of directors and/or vice-presidents shall determine that such action would expose the Trustee to personal liability to Holders of any then outstanding Series of Securities.

 

The Trustee may appoint an authenticating agent acceptable to the Issuers to authenticate Securities. An authenticating agent may authenticate Securities whenever the Trustee may do so. Each reference in this Indenture to authentication by the Trustee includes authentication by such agent. An authenticating agent has the same rights as an Agent to deal with the Issuers or an Affiliate of the Issuers.

 

Section 2.4.                                 Registrar and Paying Agent.

 

The Issuers shall maintain, with respect to each Series of Securities, at the place or places specified with respect to such Series pursuant to Section 2.2, an office or agency where Securities of such Series may be presented or surrendered for payment (“Paying Agent”), where Securities of such Series may be surrendered for registration of transfer or exchange (“Registrar”) and where notices and demands to or upon the Issuers in respect of the Securities of such Series and this Indenture may be served (“Service Agent”). The Registrar shall keep a register with respect to each Series of Securities and to their transfer and exchange. The Issuers will give prompt written notice to the Trustee of the name and address, and any change in the name or address, of each Registrar or Paying Agent. If at any time the Issuers shall fail to maintain any such required Registrar or Paying Agent or shall fail to furnish the Trustee with the name and address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Issuers hereby appoint the Trustee as their agent to receive all such presentations, surrenders, notices and demands.

 

The Issuers may also from time to time designate one or more co-registrars, additional paying agents or additional service agents and may from time to time rescind such designations; provided, however, that no such designation or rescission shall in any manner relieve the Issuers of their obligations to maintain a Registrar, Paying Agent and Service Agent in each place so specified pursuant to Section 2.2 for Securities of any Series for such purposes. The Issuers will give prompt written notice to the Trustee of any such designation or rescission and of any change in the name or address of any such co-registrar, additional paying agent or additional service agent. The term “Registrar” includes any co-registrar; the term “Paying Agent” includes any additional paying agent; and the term “Service Agent” includes any additional service agent.

 

The Issuers hereby appoint the Trustee the initial Registrar and Paying Agent and the Issuers will serve as their own Service Agent for each Series unless another Registrar, Paying Agent or Service Agent, as the case may be, is appointed prior to the time Securities of that Series are first issued.

 

10

 

Section 2.5.                                 Paying Agent to Hold Money in Trust.

 

The Issuers shall require each Paying Agent other than the Trustee to agree in writing that the Paying Agent will hold in trust, for the benefit of Securityholders of any Series of Securities, or the Trustee, all money held by the Paying Agent for the payment of principal of or interest on the Series of Securities, and will notify the Trustee in writing of any default by the Issuers in making any such payment. While any such default continues, the Trustee may require a Paying Agent to pay all money held by it to the Trustee. The Issuers at any time may require a Paying Agent to pay all money held by it to the Trustee. Upon payment over to the Trustee, the Paying Agent (if other than the Issuers or a Subsidiary of the Company) shall have no further liability for the money. If the Issuers or a Subsidiary of the Company acts as Paying Agent, it shall segregate and hold in a separate trust fund for the benefit of Securityholders of any Series of Securities all money held by it as Paying Agent.

 

Section 2.6.                                 Securityholder Lists.

 

The Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses of Securityholders of each Series of Securities and shall otherwise comply with TIA Section 312(a). If the Trustee is not the Registrar, the Issuers shall furnish to the Trustee at least ten days before each interest payment date and at such other times as the Trustee may request in writing a list, in such form and as of such date as the Trustee may reasonably require, of the names and addresses of Securityholders of each Series of Securities.

 

Section 2.7.                                 Transfer and Exchange.

 

Where Securities of a Series are presented to the Registrar or a co-registrar with a request to register a transfer or to exchange them for an equal principal amount of Securities of the same Series, the Registrar shall register the transfer or make the exchange if its requirements for such transactions are met. To permit registrations of transfers and exchanges, the Issuers shall execute and the Trustee shall, upon receipt of an Issuer Order, authenticate Securities at the Registrar’s request. No service charge shall be made for any registration of transfer or exchange (except as otherwise expressly permitted herein), but the Issuers may require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith (other than any such transfer tax or similar governmental charge payable upon exchanges pursuant to Section 2.11, 3.6 or 9.6).

 

Neither the Issuers nor the Registrar shall be required (a) to issue, register the transfer of, or exchange Securities of any Series for the period beginning at the opening of business fifteen days immediately preceding the mailing of a notice of redemption of Securities of that Series selected for redemption and ending at the close of business on the day of such mailing, or (b) to register the transfer of or exchange Securities of any Series selected, called or being called for redemption as a whole or the portion being redeemed of any such Securities selected, called or being called for redemption in part.

 

11

 

Section 2.8.                                 Mutilated, Destroyed, Lost and Stolen Securities.

 

If any mutilated Security is surrendered to the Trustee, the Issuers shall execute and the Trustee shall, upon receipt of an Issuer Order, authenticate and deliver in exchange therefor a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.

 

If there shall be delivered to the Issuers and the Trustee (a) evidence to their satisfaction of the destruction, loss or theft of any Security and (b) such security or indemnity as may be required by them to save each of them and any agent of either of them harmless, then, in the absence of notice to the Issuers or the Trustee that such Security has been acquired by a bona fide purchaser, the Issuers shall execute and the Trustee shall, upon receipt of an Issuer Order, authenticate and make available for delivery, in lieu of any such destroyed, lost or stolen Security, a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.

 

In case any such mutilated, destroyed, lost or stolen Security has become or is about to become due and payable, the Issuers in their discretion may, instead of issuing a new Security, pay such Security.

 

Upon the issuance of any new Security under this Section, the Issuers may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.

 

Every new Security of any Series issued pursuant to this Section in lieu of any destroyed, lost or stolen Security shall constitute an original additional contractual obligation of the Issuers, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of that Series duly issued hereunder.

 

The provisions of this Section are exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities.

 

Section 2.9.                                 Outstanding Securities.

 

The Securities outstanding at any time are all the Securities authenticated by the Trustee except for those canceled by it, those delivered to it for cancellation, those reductions in the interest on a Global Security effected by the Trustee in accordance with the provisions hereof and those described in this Section as not outstanding.

 

If a Security is replaced pursuant to Section 2.8, it ceases to be outstanding unless the Trustee receives proof satisfactory to it that the replaced Security is held by a bona fide purchaser.

 

If the Paying Agent (other than the Issuers, a Subsidiary of the Company or an Affiliate of the Issuers) holds on the Maturity of Securities of a Series money sufficient to pay all amounts payable in respect of such Securities on that date, then on and after that date such Securities of the Series cease to be outstanding and interest on them ceases to accrue.

 

12

 

The Issuers may purchase or otherwise acquire the Securities, whether by open market purchases, negotiated transactions or otherwise. A Security does not cease to be outstanding because the Issuers or an Affiliate of the Issuers holds the Security.

 

In determining whether the Holders of the requisite principal amount of outstanding Securities have given any request, demand, authorization, direction, notice, consent or waiver hereunder, the principal amount of a Discount Security that shall be deemed to be outstanding for such purposes shall be the amount of the principal thereof that would be due and payable as of the date of such determination upon a declaration of acceleration of the Maturity thereof pursuant to Section 6.2.

 

Section 2.10.                          Treasury Securities.

 

In determining whether the Holders of the required principal amount of Securities of a Series have concurred in any request, demand, authorization, direction, notice, consent or waiver, Securities of a Series owned by the Issuers, any Guarantor of Securities of such Series or any Affiliate of the Issuers or any such Guarantor shall be disregarded, except that for the purposes of determining whether the Trustee shall be protected in relying on any such request, demand, authorization, direction, notice, consent or waiver only Securities of a Series that a Responsible Officer of the Trustee actually knows are so owned shall be so disregarded.

 

Section 2.11.                          Temporary Securities.

 

Until definitive Securities are ready for delivery, the Issuers may prepare and the Trustee shall authenticate temporary Securities upon receipt of an Issuer Order.  Temporary Securities shall be substantially in the form of definitive Securities but may have variations that the Issuers consider appropriate for temporary Securities.  Without unreasonable delay, the Issuers shall prepare and the Trustee upon request shall authenticate definitive Securities of the same Series and date of maturity in exchange for temporary Securities.  Until so exchanged, temporary securities shall have the same rights under this Indenture as the definitive Securities.

 

Section 2.12.                          Cancellation.

 

The Issuers at any time may deliver Securities to the Trustee for cancellation. The Registrar and the Paying Agent shall forward to the Trustee any Securities surrendered to them for registration of transfer, exchange or payment. The Trustee shall cancel all Securities surrendered for transfer, exchange, payment, replacement or cancellation and, at the request of the Issuers, deliver evidence of such canceled Securities to the Issuers provided that the Trustee shall not be required to destroy Securities. The Issuers may not issue new Securities to replace Securities that it has paid or delivered to the Trustee for cancellation.

 

Section 2.13.                          Defaulted Interest.

 

If the Issuers default in a payment of interest on a Series of Securities, it shall pay the defaulted interest, plus, to the extent permitted by law, any interest payable on the defaulted interest, to the persons who are Securityholders of the Series on a subsequent special record date. The Issuers shall fix the record date and payment date. At least 10 days before the record date, the Issuers shall mail or cause to be mailed (in the case of notes held in book entry form, by

 

13

 

electronic transmission) to the Trustee and to each Securityholder of the Series a notice that states the record date, the payment date and the amount of interest to be paid. The Issuers may pay defaulted interest in any other lawful manner.

 

Section 2.14.                          Global Securities.

 

2.14.1.                                   Terms of Securities.  A Board Resolution, a supplemental indenture hereto or an Officers’ Certificate shall establish whether the Securities of a Series shall be issued in whole or in part in the form of one or more Global Securities and the Depository for such Global Security or Securities.

 

2.14.2.                                   Transfer and Exchange.  Notwithstanding any provisions to the contrary contained in Section 2.7 of the Indenture and in addition thereto, any Global Security shall be exchangeable pursuant to Section 2.7 of the Indenture for Securities registered in the names of Holders other than the Depository for such Security or its nominee only if (a) such Depository notifies the Issuers that it is unwilling or unable to continue as Depository for such Global Security or if at any time such Depository ceases to be a clearing agency registered under the Exchange Act, and, in either case, the Issuers fail to appoint a successor Depository registered as a clearing agency under the Exchange Act within 90 days of such event or (b) the Issuers execute and deliver to the Trustee an Officers’ Certificate to the effect that such Global Security shall be so exchangeable. Any Global Security that is exchangeable pursuant to the preceding sentence shall be exchangeable for Securities registered in such names as the Depository shall direct in writing in an aggregate principal amount equal to the principal amount of the Global Security with like tenor and terms.

 

Except as provided in this Section 2.14.2, a Global Security may not be transferred except as a whole by the Depository with respect to such Global Security to a nominee of such Depository, by a nominee of such Depository to such Depository or another nominee of such Depository or by the Depository or any such nominee to a successor Depository or a nominee of such a successor Depository.

 

2.14.3.                                   Legend.  Any Global Security issued hereunder shall bear a legend in substantially the following form:

 

“THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITORY OR A NOMINEE OF THE DEPOSITORY. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITORY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITORY TO A NOMINEE OF THE DEPOSITORY, BY A NOMINEE OF THE DEPOSITORY TO THE DEPOSITORY OR ANOTHER NOMINEE OF THE DEPOSITORY OR BY THE DEPOSITORY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITORY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITORY.”

 

14

 

2.14.4.                                   Acts of Holders.  The Depository, as a Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver or other action which a Holder is entitled to give or take under the Indenture.

 

2.14.5.                                   Payments.  Notwithstanding the other provisions of this Indenture, unless otherwise specified as contemplated by Section 2.2, payment of the principal of and interest, if any, on any Global Security shall be made to the Holder thereof.

 

2.14.6.                                   Consents, Declaration and Directions.  Except as provided in Section 2.14.5, the Issuers, the Guarantors, if any, the Trustee and any Agent shall treat a person as the Holder of such principal amount of outstanding Securities of such Series represented by a Global Security as shall be specified in a written statement of the Depository with respect to such Global Security, for purposes of obtaining any consents, declarations, waivers or directions required to be given by the Holders pursuant to this Indenture.

 

Section 2.15.                          CUSIP Numbers.

 

The Issuers in issuing the Securities may use “CUSIP” numbers (if then generally in use), and, if so, the Trustee shall use “CUSIP” numbers in notices of redemption as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Securities or as contained in any notice of a redemption and that reliance may be placed only on the other elements of identification printed on the Securities, and any such redemption shall not be affected by any defect in or omission of such numbers.

 

ARTICLE III.
 REDEMPTION

 

Section 3.1.                                 Notice to Trustee.

 

The Issuers may, with respect to any Series of Securities, reserve the right to redeem and pay the Series of Securities or may covenant to redeem and pay the Series of Securities or any part thereof prior to the Stated Maturity thereof at such time and on such terms as provided for in such Securities. If a Series of Securities is redeemable and the Issuers want or are obligated to redeem prior to the Stated Maturity thereof all or part of the Series of Securities pursuant to the terms of such Securities, they shall notify the Trustee in writing of the redemption date and the principal amount of Series of Securities to be redeemed. The Issuers shall give written notice at least 35 days before the redemption date (or such shorter notice as may be acceptable to the Trustee).

 

Section 3.2.                                 Selection of Securities to be Redeemed.

 

Unless otherwise indicated for a particular Series by a Board Resolution, supplemental indenture or Officers’ Certificate, if less than all the Securities of a Series are to be redeemed, the Trustee shall select the Securities of the Series to be redeemed by lot or in accordance with the Depository’s applicable procedures. The Trustee shall make the selection from Securities of the Series outstanding not previously called for redemption. The Trustee may select for redemption

 

15

 

portions of the principal of Securities of the Series that have denominations larger than $1,000. Securities of the Series and portions of them it selects shall be in amounts of $1,000 or whole multiples of $1,000 or, with respect to Securities of any Series issuable in other denominations pursuant to Section 2.2.10, the minimum principal denomination for each Series and integral multiples thereof. Provisions of this Indenture that apply to Securities of a Series called for redemption also apply to portions of Securities of that Series called for redemption.

 

Section 3.3.                                 Notice of Redemption.

 

Unless otherwise indicated for a particular Series by Board Resolution, a supplemental indenture hereto or an Officers’ Certificate, at least 30 days but not more than 60 days before a redemption date, the Issuers shall mail a notice of redemption by first-class mail (in the case of notes held in book entry form, by electronic transmission) to each Holder whose Securities are to be redeemed.

 

The notice shall identify the Securities of the Series to be redeemed and shall state:

 

(a)                                 the redemption date;

 

(b)                                 the redemption price;

 

(c)                                  the name and address of the Paying Agent;

 

(d)                                 that Securities of the Series called for redemption must be surrendered to the Paying Agent to collect the redemption price;

 

(e)                                  that interest on Securities of the Series called for redemption ceases to accrue on and after the redemption date;

 

(f)                                   the CUSIP number, if any; and

 

(g)                                  any other information as may be required by the terms of the particular Series or the Securities of a Series being redeemed.

 

At the Issuers’ written request, the Trustee shall give the notice of redemption in the Issuers’ name and at its expense.

 

Section 3.4.                                 Effect of Notice of Redemption.

 

Once notice of redemption is mailed or published as provided in Section 3.3, Securities of a Series called for redemption become due and payable on the redemption date and at the redemption price. A notice of redemption may not be conditional. Upon surrender to the Paying Agent, such Securities shall be paid at the redemption price plus accrued interest to the redemption date.

 

16

 

Section 3.5.                                 Deposit of Redemption Price.

 

On or before 11:00 a.m., New York City time, on the redemption date, the Issuers shall deposit with the Paying Agent money sufficient to pay the redemption price of and accrued interest, if any, on all Securities to be redeemed on that date.

 

Section 3.6.                                 Securities Redeemed in Part.

 

Upon surrender of a Security that is redeemed in part, the Trustee shall, upon receipt of an Issuer Order, authenticate for the Holder a new Security of the same Series and the same maturity equal in principal amount to the unredeemed portion of the Security surrendered.

 

ARTICLE IV.
 COVENANTS

 

Section 4.1.                                 Payment of Principal and Interest.

 

The Issuers covenant and agree that they will duly and punctually pay or cause to be paid when due the principal of (including the redemption price upon redemption pursuant to Article 3, if applicable), and premium, if any, and interest on each of the Securities at the places, at the respective times and in the manner provided herein and in the Securities; provided that the Issuers may withhold from payments of interest and upon redemption pursuant to Article 3, if applicable, maturity or otherwise, any amounts the Issuers are required to withhold by law.

 

Section 4.2.                                 SEC Reports.

 

The Company shall deliver to the Trustee within 15 days after it files them with the SEC copies of the annual reports and of the information, documents, and other reports (or copies of such portions of any of the foregoing as the SEC may by rules and regulations prescribe) which the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act. The Company also shall comply with the other provisions of TIA Section 314(a). Reports, information and documents filed with the SEC via the EDGAR system will be deemed to be delivered to the Trustee as of the time of such filing via EDGAR for purposes of this Section 4.2. Delivery of such reports, information and documents to the Trustee is for informational purposes only and the Trustee’s receipt of such shall not constitute constructive notice of any information contained therein or determinable from information contained therein, including the Issuers’ compliance with any of their covenants hereunder (as to which the Trustee is entitled to rely exclusively on an Officers’ Certificate).

 

Section 4.3.                                 Compliance Certificate.

 

The Issuers and each Guarantor (to the extent that such Guarantor is so required under the TIA) shall deliver to the Trustee, within 120 days after the end of each fiscal year of the Issuers, an Officers’ Certificate stating that a review of the activities of the Issuers and the Subsidiaries of the Company during the preceding fiscal year has been made under the supervision of the signing Officers with a view to determining whether the Issuers and any Guarantor have kept, observed, performed and fulfilled their obligations under this Indenture, and further stating, as to each such Officer signing such certificate, that to the best of his/her knowledge the Issuers have kept, observed, performed and fulfilled each and every covenant contained in this Indenture and are not in default in the performance or observance of any of the terms, provisions and

 

17

 

conditions hereof (or, if a Default or Event of Default shall have occurred, describing all such Defaults or Events of Default of which he or she may have knowledge).

 

The Issuers will, so long as any of the Securities are outstanding, deliver to the Trustee, promptly upon becoming aware of any Default or Event of Default, an Officers’ Certificate specifying such Default or Event of Default and what action the Issuers are taking or proposes to take with respect thereto.

 

Section 4.4.                                 Stay, Extension and Usury Laws.

 

The Issuers covenant (to the extent that they may lawfully do so) that they will not at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in force, which may affect the covenants or the performance of this Indenture or the Securities and the Issuers (to the extent they may lawfully do so) hereby expressly waive all benefit or advantage of any such law and covenant that they will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law has been enacted.

 

Section 4.5.                                 Corporate Existence.

 

Subject to Article V, the Issuers will do or cause to be done all things necessary to preserve and keep in full force and effect its existence and rights (charter and statutory); provided that the Issuers shall not be required to preserve any such right if the Issuers shall determine that the preservation thereof is no longer desirable in the conduct of the business of the Issuers and that the loss thereof is not disadvantageous in any material respect to the Holders.

 

ARTICLE V.
 SUCCESSORS

 

Section 5.1.                                 Issuer May Consolidate on Certain Terms.

 

Nothing contained in this Indenture or in the Securities shall prevent any consolidation or merger of an Issuer with or into any other person or persons (whether or not affiliated with the Issuer), or successive consolidations or mergers in which either the Issuer will be the continuing entity or the Issuer or its successor or successors shall be a party or parties, or shall prevent any sale, conveyance, transfer or lease of all or substantially all of the property of the Issuer, to any other person (whether or not affiliated with the Issuer); provided, however, that the following conditions are met:

 

(a)                                 the Issuer shall be the continuing entity, or the successor entity (if other than the Issuer) formed by or resulting from any consolidation or merger or which shall have received the transfer of assets shall expressly assume payment of the principal of and interest on all of the Securities and the due and punctual performance and observance of all of the covenants and conditions in this Indenture;

 

(b)                                 immediately after giving effect to such transaction, no Default or Event of Default shall have occurred and be continuing; and

 

18

 

(c)                                  either the Issuer or the successor person, in either case, shall have delivered to the Trustee an Officers’ Certificate and Opinion of Counsel, stating that such consolidation, merger, sale, conveyance, transfer or lease and, if a supplemental indenture is required in connection with such transaction, such supplemental indenture, complies with this Section 5.1 and that all conditions precedent herein provided for relating to such transaction have been complied with.

 

Except in the case of a substantially concurrent consolidation, merger, sale, conveyance, transfer or lease of all or substantially all of the property of a Guarantor in compliance with Section 5.3, no such consolidation, merger, sale, conveyance, transfer or lease shall be permitted by this Section 5.1 unless prior thereto such Guarantor shall have delivered to the Trustee a Guarantor’s Officers’ Certificate, stating that the Guarantor’s obligations hereunder shall remain in full force and effect thereafter.

 

Section 5.2.                                 Issuer Successor to be Substituted.

 

Upon any consolidation by an Issuer with or merger of an Issuer into any other person or any sale, conveyance, transfer or lease of all or substantially all of the properties and assets of the Issuer to any person in accordance with Section 5.1 hereof, the successor person formed by such consolidation or into which the Issuer is merged or to which such sale, conveyance, transfer or lease is made shall succeed to, and be substituted for, and may exercise every right and power of, the Issuer under this Indenture with the same effect as if such successor person had been named as the Issuer herein, and thereafter the predecessor person shall be released from all obligations and covenants under this Indenture and the Issuer; provided, however, that the predecessor Issuer shall not be relieved from the obligation to pay the principal of and interest on the Securities except in the case of a sale of all or substantially all of the Issuer’s assets in a transaction that is subject to, and that complies with the provisions of, Section 5.1 hereof.

 

In case of any such consolidation, merger, sale, conveyance, transfer or lease, such changes in phraseology and form (but not in substance) may be made in the Securities thereafter to be issued as may be appropriate.

 

Section 5.3.                                 A Guarantor May Consolidate on Certain Terms.

 

Nothing contained in this Indenture or in the Securities shall prevent any consolidation or merger of a Guarantor with or into any other person or persons (whether or not affiliated with such Guarantor), or successive consolidations or mergers in which either a Guarantor will be the continuing entity or a Guarantor or its successor or successors shall be a party or parties, or shall prevent any sale, conveyance, transfer or lease of all or substantially all of the property of a Guarantor, to any other person (whether or not affiliated with such Guarantor); provided, however, that the following conditions are met:

 

(a)                                 such Guarantor shall be the continuing entity, or the successor entity (if other than such Guarantor) formed by or resulting from any consolidation or merger or which shall have received the transfer of assets shall expressly assume the obligations of such Guarantor under the Guarantee and the due and punctual performance and observance of all of the covenants and conditions in this Indenture;

 

19

 

(b)                                 immediately after giving effect to such transaction, no Default or Event of Default shall have occurred and be continuing; and

 

(c)                                  either such Guarantor or the successor person, in either case, shall have delivered to the Trustee an Officers’ Certificate of such Guarantor and Opinion of Counsel, stating that such consolidation, sale, merger, conveyance, transfer or lease and such supplemental indenture comply with this Section 5.3 and that all conditions precedent herein provided for relating to such transaction have been complied with.

 

Section 5.4.                                 Guarantor Successor to be Substituted.

 

Upon any consolidation or merger or any sale, conveyance, transfer or lease of all or substantially all of the properties and assets of a Guarantor to any person in accordance with Section 5.3, the successor person formed by such consolidation or into which such Guarantor is merged or to which such sale, conveyance, transfer or lease is made shall succeed to, and be substituted for, and may exercise every right and power of, such Guarantor under this Indenture with the same effect as if such successor person had been named as such Guarantor herein, and thereafter, the predecessor person shall be released from all obligations and covenants under this Indenture; provided, however, that the predecessor Guarantor shall not be relieved from the obligation to guarantee the payment of the principal of and interest on the Securities except in the case of a sale of all or substantially all of such Guarantor’s assets in a transaction that is subject to, and that complies with the provisions of, Section 5.3 hereof.

 

In case of any such consolidation, merger, sale, conveyance, transfer or lease, such changes in phraseology and form (but not in substance) may be made in the notes thereafter to be issued as may be appropriate.

 

ARTICLE VI.
 DEFAULTS AND REMEDIES

 

Section 6.1.                                 Events of Default.

 

“Event of Default,” wherever used herein with respect to Securities of any Series, means any one of the following events, unless in the establishing Board Resolution, supplemental indenture or Officers’ Certificate, it is provided that such Series shall not have the benefit of said Event of Default:

 

(a)                                 default in the payment of any interest on any Security of that Series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of such payment is deposited by the Issuers with the Trustee or with a Paying Agent prior to the expiration of such period of 30 days); or

 

(b)                                 default in the payment of principal of any Security of that Series at its Maturity; or

 

(c)                                  default in the performance or breach of any covenant or warranty of the Issuers (or, in the case the Securities of that Series are subject to a Guarantee, any Guarantor of such Guarantee) in this Indenture (other than a covenant or warranty for

 

20

 

which the consequences of nonperformance or breach are addressed elsewhere in this Section 6.1 and other than a covenant or warranty that has been included in this Indenture solely for the benefit of Series of Securities other than that Series), which default continues uncured for a period of 60 days after there has been given to the Issuers by the Trustee or to the Issuers and the Trustee by the Holders of not less than a majority in principal amount of the outstanding Securities of that Series a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a “Notice of Default” hereunder; or

 

(d)                                 the Issuers, any Guarantor or any Significant Subsidiary pursuant to or under or within the meaning of any Bankruptcy Law:

 

(i)                                     commences a voluntary case or proceeding seeking liquidation, reorganization or other relief with respect to the Issuers, any Guarantor or a Significant Subsidiary or its debts or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of the Issuers, any Guarantor or a Significant Subsidiary or any substantial part of the property of the Issuers, any Guarantor or a Significant Subsidiary,

 

(ii)                                  consents to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against the Issuers, any Guarantor or a Significant Subsidiary,

 

(iii)                               consents to the appointment of a custodian of it or for all or substantially of its property, or

 

(iv)                              makes a general assignment for the benefit of its creditors, or

 

(e)                                  an involuntary case or other proceeding shall be commenced against the Issuers, any Guarantor or any Significant Subsidiary seeking liquidation, reorganization or other relief with respect to the Issuers, any Guarantor or a Significant Subsidiary or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of the Issuers, any Guarantor or a Significant Subsidiary or any substantial part of the property of the Issuers, any Guarantor or a Significant Subsidiary, and such involuntary case or other proceeding shall remain undismissed and unstayed for a period of sixty (60) calendar days; or

 

(f)                                   a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that:

 

(i)                                     is for relief against the Issuers, any Guarantor or any of Significant Subsidiary in an involuntary case or proceeding,

 

(ii)                                  appoints a trustee, receiver, liquidator, custodian or other similar official of the Issuers, any Guarantor or a Significant Subsidiary or any substantial part of the property of the Issuers, any Guarantor or a Significant Subsidiary, or

 

21

 

(iii)                               orders the liquidation of the Issuers, any Guarantor or a Significant Subsidiary; and, in each case in this clause (f), the order or decree remains unstayed and in effect for sixty (60) calendar days; or

 

(g)                                  any other Event of Default provided with respect to Securities of that Series, which is specified in a Board Resolution, a supplemental indenture hereto or an Officers’ Certificate, in accordance with Section 2.2.18.

 

The term “Bankruptcy Law” means title 11, U.S. Code or any similar Federal or State law for the relief of debtors.  The term “Custodian” means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.

 

Section 6.2.                                 Acceleration of Maturity; Rescission and Annulment.

 

If an Event of Default with respect to Securities of any Series at the time outstanding occurs and is continuing (other than an Event of Default referred to in Section 6.1(d), (e) or (f)), then in every such case the Trustee or the Holders of not less than 25% in principal amount of the outstanding Securities of that Series may declare the principal amount (or, if any Securities of that Series are Discount Securities, such portion of the principal amount as may be specified in the terms of such Securities) of and accrued and unpaid interest, if any, on all of the Securities of that Series to be due and payable immediately, by a notice in writing to the Issuers (and to the Trustee if given by Holders), and upon any such declaration such principal amount (or specified amount) and accrued and unpaid interest, if any, shall become immediately due and payable. If an Event of Default specified in Section 6.1(d), (e) or (f) shall occur, the principal amount (or specified amount) of and accrued and unpaid interest, if any, on all outstanding Securities shall automatically become and be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder.

 

At any time after the principal amount of and premium, if any, and interest on the Securities shall have been so declared due and payable, and before any judgment or decree for the payment of the monies due shall have been obtained or entered as hereinafter provided, Holders of a majority in aggregate principal amount of the Securities then outstanding on behalf of the Holders of all of the Securities then outstanding, by written notice to the Issuers and to the Trustee, may waive all Defaults or Events of Default and rescind and annul such declaration and its consequences, subject in all respects to Section 6.13 hereof, if: (a) all Events of Default, other than the nonpayment of the principal amount and any accrued and unpaid interest that have become due solely because of such acceleration, have been cured or waived; and (b) the Issuers or any Guarantor has deposited with the Trustee all required payments of the principal of and interest on, the Securities, plus the reasonable compensation and reimbursement for the Trustee’s expenses, disbursements and advances pursuant to Section 7.7. No such rescission and annulment shall extend to or shall affect any subsequent default or Event of Default, or shall impair any right consequent thereon. The Issuers shall notify in writing a Responsible Officer of the Trustee, promptly upon becoming aware thereof, of any Event of Default, as provided in Section 4.3.

 

22

 

Section 6.3.                                 Collection of Indebtedness and Suits for Enforcement by Trustee.

 

The Issuers covenant that if a:

 

(a)                                 default is made in the payment of any interest on any Security when such interest becomes due and payable and such default continues for a period of 30 days, or

 

(b)                                 default is made in the payment of principal of any Security at the Maturity thereof, or

 

(c)                                  default is made in the deposit of any sinking fund payment when and as due by the terms of a Security,

 

then, the Issuers will, upon demand of the Trustee, pay to it, for the benefit of the Holders of such Securities, the whole amount then due and payable on such Securities for principal and interest and, to the extent that payment of such interest shall be legally enforceable, interest on any overdue principal and any overdue interest at the rate or rates prescribed therefor in such Securities, and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, including the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel.

 

If the Issuers fails to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against the Issuers, any Guarantor or any other obligor upon such Securities and collect the moneys adjudged or deemed to be payable in the manner provided by law out of the property of the Issuers, any Guarantor or any other obligor upon such Securities, wherever situated.

 

If an Event of Default with respect to any Securities of any Series occurs and is continuing, the Trustee may in its discretion proceed to protect and enforce its rights and the rights of the Holders of Securities of such Series by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this Indenture or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.

 

Section 6.4.                                 Trustee May File Proofs of Claim.

 

In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to the Issuers or any other obligor upon the Securities or the property of the Issuers or of such other obligor or their creditors, the Trustee (irrespective of whether the principal of the Securities shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any demand on the Issuers for the payment of overdue principal or interest) shall be entitled and empowered, by intervention in such proceeding or otherwise,

 

(a)                                 to file and prove a claim for the whole amount of principal and interest owing and unpaid in respect of the Securities and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any

 

23

 

claim for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceeding, and

 

(b)                                 to collect and receive any moneys or other property payable or deliverable on any such claims and to distribute the same,

 

and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due it for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 7.7.

 

Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting the Securities or the rights of any Holder thereof or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding.

 

Section 6.5.                                 Trustee May Enforce Claims Without Possession of Securities.

 

All rights of action and claims under this Indenture, the Securities or any Guarantee may be prosecuted and enforced by the Trustee without the possession of any of the Securities or the production thereof in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall, after provision for the payment of the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Securities in respect of which such judgment has been recovered.

 

Section 6.6.                                 Application of Money Collected.

 

Any money collected by the Trustee pursuant to this Article shall be applied in the following order, at the date or dates fixed by the Trustee and, in case of the distribution of such money on account of principal or interest, upon presentation of the Securities and the notation thereon of the payment if only partially paid and upon surrender thereof if fully paid:

 

First:                                                                                                                     To the payment of all amounts due the Trustee under Section 7.7; and

 

Second:                                                                                                    To the payment of the amounts then due and unpaid for principal of and interest on the Securities in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal and interest, respectively; and

 

Third:                                                                                                               To the Issuers or any applicable Guarantor, as the case may be.

 

24

 

Section 6.7.                                 Limitation on Suits.

 

No Holder of any Security of any Series shall have any right to institute any proceeding, judicial or otherwise, with respect to this Indenture, or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless:

 

(a)                                 such Holder has previously given written notice to the Trustee of a continuing Event of Default with respect to the Securities of that Series;

 

(b)                                 the Holders of at least 25% in aggregate principal amount of the outstanding Securities of that Series shall have made written request to the Trustee to institute proceedings in respect of such Event of Default in its own name as Trustee hereunder;

 

(c)                                  such Holder or Holders have offered to the Trustee indemnity or security against losses, costs, expenses and liabilities to be incurred in compliance with such request;

 

(d)                                 the Trustee for 60 days after its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding; and

 

(e)                                  no direction inconsistent with such written request has been given to the Trustee during such 60-day period by the Holders of a majority in principal amount of the outstanding Securities of that Series,

 

it being understood and intended that no one or more of such Holders shall have any right in any manner whatever by virtue of, or by availing of, any provision of this Indenture to affect, disturb or prejudice the rights of any other of such Holders, or to obtain or to seek to obtain priority or preference over any other of such Holders or to enforce any right under this Indenture, except in the manner herein provided and for the equal and ratable benefit of all such Holders of the applicable Series.

 

Section 6.8.                                 Unconditional Right of Holders to Receive Principal and Interest.

 

Notwithstanding any other provision in this Indenture, the Holder of any Security shall have the right, which is absolute and unconditional, to receive payment of the principal of and interest, if any, on such Security on the Stated Maturity or Stated Maturities expressed in such Security (or, in the case of redemption, on the redemption date) and to institute suit for the enforcement of any such payment, and such rights shall not be impaired without the consent of such Holder.

 

Section 6.9.                                 Restoration of Rights and Remedies.

 

If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding, the Issuers, any Guarantor, the Trustee and the Holders shall be restored severally and respectively to their former positions hereunder and thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted.

 

25

 

Section 6.10.                          Rights and Remedies Cumulative.

 

Except as otherwise provided with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities in Section 2.8, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not, to the extent permitted by law, prevent the concurrent assertion or employment of any other appropriate right or remedy.

 

Section 6.11.                          Delay or Omission Not Waiver.

 

No delay or omission of the Trustee or of any Holder of any Securities to exercise any right or remedy accruing upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein. Every right and remedy given by this Article or by law to the Trustee or to the Holders may be exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders, as the case may be.

 

Section 6.12.                          Control by Holders.

 

The Holders of a majority in principal amount of the outstanding Securities of any Series shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the Securities of such Series, provided that

 

(a)                                 such direction shall not be in conflict with any rule of law or with this Indenture,

 

(b)                                 the Trustee may take any other action deemed proper by the Trustee which is not inconsistent with such direction, and

 

(c)                                  subject to the provisions of Section 6.1, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer of the Trustee, determine that the proceeding so directed would involve the Trustee in personal liability.

 

Section 6.13.                          Waiver of Past Defaults.

 

The Holders of not less than a majority in principal amount of the outstanding Securities of any Series may on behalf of the Holders of all the Securities of such Series waive any past Default hereunder with respect to such Series and its consequences, except a Default (a) in the payment of the principal of or interest on any Security of such Series (provided, however, that the Holders of a majority in principal amount of the outstanding Securities of any Series may rescind an acceleration and its consequences, including any related payment default that resulted from such acceleration) or (b) in respect of a covenant or provision hereof which cannot be modified or amended without the consent of the Holder of each outstanding Security of such

 

26

 

Series affected. Upon any such waiver, such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured, for every purpose of this Indenture; but no such waiver shall extend to any subsequent or other Default or impair any right consequent thereon.

 

Section 6.14.                          Undertaking for Costs.

 

All parties to this Indenture agree, and each Holder of any Security by its acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken, suffered or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys’ fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this Section shall not apply to any suit instituted by the Issuers or any Guarantor, to any suit instituted by the Trustee, to any suit instituted by any Holder, or group of Holders, holding in the aggregate more than 10% in principal amount of the outstanding Securities of any Series, or to any suit instituted by any Holder for the enforcement of the payment of the principal of or interest on any Security on or after the Stated Maturity or Stated Maturities expressed in such Security (or, in the case of redemption, on the redemption date).

 

ARTICLE VII.
 TRUSTEE

 

Section 7.1.                                 Duties of Trustee.

 

(a)                                 If an Event of Default has occurred and is continuing, the Trustee shall exercise the rights and powers vested in it by this Indenture and use the same degree of care and skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of such person’s own affairs.

 

(b)                                 Except during the continuance of an Event of Default:

 

(i)                                     The Trustee need perform only those duties that are specifically set forth in this Indenture and no others.

 

(ii)                                  In the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon Officers’ Certificates or Opinions of Counsel furnished to the Trustee and conforming to the requirements of this Indenture; however, in the case of any such Officers’ Certificates or Opinions of Counsel which by any provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall examine such Officers’ Certificates and Opinions of Counsel to determine whether or not they conform to the requirements of this Indenture.

 

(c)                                  The Trustee may not be relieved from liability for its own negligent action, its own negligent failure to act or its own willful misconduct, except that:

 

27

 

(i)                                     This paragraph does not limit the effect of paragraph (b) of this Section.

 

(ii)                                  The Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it is proved that the Trustee was negligent in ascertaining the pertinent facts.

 

(iii)                               The Trustee shall not be liable with respect to any action taken, suffered or omitted to be taken by it with respect to Securities of any Series in good faith in accordance with the direction of the Holders of a majority in principal amount of the outstanding Securities of such Series relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture with respect to the Securities of such Series.

 

(iv)                              No provision of this Indenture shall require the Trustee to risk its own funds or otherwise incur any financial liability in the performance of any of its duties, or in the exercise of any of its rights or powers, if it shall have reasonable grounds for believing that repayment of such funds or adequate indemnity against such risk is not reasonably assured to it.

 

(d)                                 The Trustee may refuse to perform any duty or exercise any right or power at the request or direction of any Holder unless it receives indemnity or security reasonably satisfactory to it against any loss, liability or expense.

 

(e)                                  The Trustee shall not be liable for interest on any money received by it except as the Trustee may agree in writing with the Issuers. Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law.

 

(f)                                   The Paying Agent, the Registrar and any authenticating agent shall be entitled to the protections, immunities and standard of care as are set forth in this Section 7.1 with respect to the Trustee.

 

Section 7.2.                                 Rights of Trustee.

 

(a)                                 The Trustee may conclusively rely on and shall be protected in acting or refraining from acting upon any document (whether in its original or facsimile form) believed by it to be genuine and to have been signed or presented by the proper person. The Trustee need not investigate any fact or matter stated in the document.

 

(b)                                 Before the Trustee acts or refrains from acting, it shall be entitled to receive an Officers’ Certificate and an Opinion of Counsel. The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on such Officers’ Certificate.

 

(c)                                  The Trustee may act through agents and shall not be responsible for the misconduct or negligence of any agent appointed with due care. No Depository shall be

 

28

 

deemed an agent of the Trustee and the Trustee shall not be responsible for any act or omission by any Depository.

 

(d)                                 The Trustee shall not be liable for any action it takes or omits to take in good faith which it believes to be authorized or within its rights or powers, provided that the Trustee’s conduct does not constitute negligence or willful misconduct.

 

(e)                                  The Trustee may consult with counsel of its selection and the advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder and in good faith and in reliance thereon.

 

(f)                                   The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders of Securities pursuant to this Indenture unless such Holders shall have offered to the Trustee security or indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.

 

(g)                                  The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit.

 

(h)                                 The Trustee shall not be deemed to have notice of any breach hereof, Default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a breach, Default or Event of Default is received by the Trustee at the Corporate Trust Office of the Trustee, and such notice references the Securities generally or the Securities of a particular Series and this Indenture.

 

(i)                                     Any permissive right or authority granted to the Trustee shall not be construed as a mandatory duty.

 

(j)                                    The Trustee may request that the Issuers deliver an Officers’ Certificate setting forth the names of individuals and/or titles of officers authorized at such time to take specified actions pursuant to this Indenture, which Officers’ Certificate may be signed by any person authorized to sign an Officers’ Certificate, including any person specified as so authorized in any such certificate previously delivered and not superseded.

 

(k)                                 In no event shall the Trustee be responsible or liable for special, indirect, punitive or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action arising in connection with the Indenture.

 

(l)                                     The Trustee shall not be required to give any bond or surety in respect of the execution of the trusts and powers or otherwise in respect of the Indenture.

 

29

 

(m)                             Under no circumstances shall the Trustee be liable in its individual capacity for the obligations evidenced by the Securities.

 

Section 7.3.                                 Individual Rights of Trustee.

 

The Trustee in its individual or any other capacity may become the owner or pledgee of Securities and may otherwise deal with the Issuers, any Guarantor or any Affiliate of the Issuers or any Guarantor with the same rights it would have if it were not Trustee subject to TIA provisions regarding conflicts of interests.  Any Agent may do the same with like rights.  The Trustee is also subject to Sections 7.10 and 7.11.

 

Section 7.4.                                 Trustee’s Disclaimer.

 

The Trustee makes no representation as to the validity or adequacy of this Indenture or the Securities, it shall not be accountable for the Issuers’ use of the proceeds from the Securities, and it shall not be responsible for any statement in the Securities other than its authentication.

 

Section 7.5.                                 Notice of Defaults.

 

If a Default or Event of Default occurs and is continuing with respect to the Securities of any Series and if a Responsible Officer of the Trustee has actual knowledge of such Default or Event of Default, the Trustee shall mail to each Securityholder of the Securities of that Series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a Responsible Officer of the Trustee has knowledge of such Default or Event of Default. Except in the case of a Default or Event of Default in payment of principal of or interest on any Security of any Series, the Trustee may withhold the notice if and so long as its corporate trust committee or a committee of its Responsible Officers in good faith determines that withholding the notice is in the interests of Securityholders of that Series.

 

Section 7.6.                                 Reports by Trustee to Holders.

 

Within 60 days after May 15 in each year, the Trustee shall transmit by mail to all Securityholders, as their names and addresses appear on the register kept by the Registrar, a brief report dated as of such May 15, in accordance with, and to the extent required under, TIA Section 313.

 

A copy of each report at the time of its mailing to Securityholders of any Series shall be filed with the SEC and each stock exchange on which the Securities of that Series are listed. The Issuers shall promptly notify the Trustee when Securities of any Series are listed on any stock exchange.

 

Section 7.7.                                 Compensation and Indemnity.

 

The Issuers shall pay to the Trustee from time to time compensation for their services as the Issuers and the Trustee shall from time to time agree upon in writing. The Trustee’s compensation shall not be limited by any law on compensation of a trustee of an express trust. The Issuers shall reimburse the Trustee upon request for all reasonable out-of-pocket expenses

 

30

 

incurred by it. Such expenses shall include the reasonable compensation and expenses of the Trustee’s agents and counsel.

 

The Issuers shall indemnify, protect and hold each of the Trustee and any predecessor Trustee (including the cost of defending itself) harmless from and against any and all loss, liability, damages, costs or expense, including taxes (other than taxes based upon, measured by or determined by the income of the Trustee) incurred by it except as set forth in the next paragraph in the performance of its duties under this Indenture as Trustee or Agent. The Trustee shall notify the Issuers promptly of any claim for which it may seek indemnity. The Issuers shall defend the claim and the Trustee shall cooperate in the defense. The Trustee may have one separate counsel and the Issuers shall pay the reasonable fees and expenses of such counsel. The Issuers need not pay for any settlement made without their consent, which consent shall not be unreasonably withheld. This indemnification shall apply to officers, directors, employees, shareholders and agents of the Trustee.

 

The Issuers need not reimburse any expense or indemnify against any loss or liability incurred by the Trustee or by any officer, director, employee, shareholder or agent of the Trustee through negligence or willful misconduct.

 

To secure the Issuers’ payment obligations in this Section, the Trustee shall have a lien prior to the Securities of any Series on all money or property held or collected by the Trustee, except that held in trust to pay principal of and interest on particular Securities of that Series.

 

When the Trustee incurs expenses or renders services after an Event of Default specified in Section 6.1(d) or (e) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law.

 

The provisions of this Section shall survive the termination of this Indenture and the resignation or removal of the Trustee.

 

Section 7.8.                                 Replacement of Trustee.

 

A resignation or removal of the Trustee and appointment of a successor Trustee shall become effective only upon the successor Trustee’s acceptance of appointment as provided in this Section.

 

The Trustee may resign with respect to the Securities of one or more Series by so notifying the Issuers at least 30 days prior to the date of the proposed resignation. The Holders of a majority in principal amount of the Securities of any Series may remove the Trustee with respect to that Series by so notifying the Trustee and the Issuers. The Issuers may remove the Trustee with respect to Securities of one or more Series if:

 

(a)                                 the Trustee fails to comply with Section 7.10;

 

(b)                                 the Trustee is adjudged bankrupt or insolvent or an order for relief is entered with respect to the Trustee under any Bankruptcy Law;

 

(c)                                  a Custodian or public officer takes charge of the Trustee or its property; or

 

31

 

(d)                                 the Trustee becomes incapable of acting.

 

If the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Issuers shall promptly appoint a successor Trustee. Within one year after the successor Trustee takes office, the Holders of a majority in principal amount of the then outstanding Securities may appoint a successor Trustee to replace the successor Trustee appointed by the Issuers.

 

If a successor Trustee with respect to the Securities of any one or more Series does not take office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Issuers or the Holders of at least a majority in principal amount of the Securities of the applicable Series may petition any court of competent jurisdiction for the appointment of a successor Trustee.

 

A successor Trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the Issuers. Immediately after that, the retiring Trustee shall transfer all property held by it as Trustee to the successor Trustee subject to the lien provided for in Section 7.7, the resignation or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee with respect to each Series of Securities for which it is acting as Trustee under this Indenture. A successor Trustee shall mail a notice of its succession to each Securityholder of each such Series. Notwithstanding replacement of the Trustee pursuant to this Section 7.8, the Issuers’ obligations under Section 7.7 hereof shall continue for the benefit of the retiring Trustee with respect to expenses and liabilities incurred by it prior to such replacement.

 

Section 7.9.                                 Successor Trustee by Merger, Etc.

 

If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust business to, another corporation, the successor corporation without any further act shall be the successor Trustee.

 

Section 7.10.                          Eligibility; Disqualification.

 

This Indenture shall always have a Trustee who satisfies the requirements of TIA Section 310(a)(1), (2) and (5). The Trustee shall always have a combined capital and surplus of at least $25,000,000 as set forth in its most recent published annual report of condition. The Trustee shall comply with TIA Section 310(b).

 

Section 7.11.                          Preferential Collection of Claims Against Issuers.

 

The Trustee is subject to TIA Section 311(a), excluding any creditor relationship listed in TIA Section 311(b). A Trustee who has resigned or been removed shall be subject to TIA Section 311(a) to the extent indicated.

 

32

 

ARTICLE VIII.
 SATISFACTION AND DISCHARGE; DEFEASANCE

 

Section 8.1.                                 Satisfaction and Discharge of Indenture.

 

This Indenture shall upon Issuer Order cease to be of further effect (except as hereinafter provided in this Section 8.1), and the Trustee, at the request and expense of the Issuers, shall execute proper instruments acknowledging satisfaction and discharge of this Indenture, when:

 

(a)                                 either:

 

(i)                                     all Securities theretofore authenticated and delivered (other than Securities that have been destroyed, lost or stolen and that have been replaced or paid) have been delivered to the Trustee for cancellation; or

 

(ii)                                  all such Securities not theretofore delivered to the Trustee for cancellation:

 

(1)                                 have become due and payable, or

 

(2)                                 will become due and payable at their Stated Maturity within one year, or

 

(3)                                 have been called for redemption or are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Issuers, or

 

(4)                                 are deemed paid and discharged pursuant to Section 8.3, as applicable;

 

and the Issuers , in the case of (1), (2) or (3) above, have irrevocably deposited or caused to be deposited with the Trustee as trust funds in trust an amount sufficient for the purpose of paying and discharging the entire indebtedness on such Securities not theretofore delivered to the Trustee for cancellation, for principal and interest to the date of such deposit (in the case of Securities which have become due and payable on or prior to the date of such deposit) or to the Stated Maturity or redemption date, as the case may be;

 

(b)                                 the Issuers have paid or caused to be paid all other sums payable hereunder by the Issuers; and

 

(c)                                  the Issuers have delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the satisfaction and discharge of this Indenture have been complied with.

 

Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Issuers to the Trustee under Section 7.7, and, if money shall have been deposited with the Trustee pursuant to clause (a) of this Section, the provisions of Sections 2.4, 2.7, 2.8, 8.2 and 8.5 shall survive.

 

If the Issuers exercise the satisfaction and discharge provisions in compliance with this Indenture with respect to Securities of a particular Series that are entitled to the benefit of the

 

33

 

Guarantee of any Guarantor, such Guarantee will terminate with respect to that series of Securities.

 

Section 8.2.                                 Application of Trust Funds; Indemnification.

 

(a)                                 Subject to the provisions of Section 8.5, all money deposited with the Trustee pursuant to Section 8.1, all money and U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to Section 8.3 or 8.4 and all money received by the Trustee in respect of U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to Section 8.3 or 8.4, shall be held in trust and applied by it, in accordance with the provisions of the Securities and this Indenture, to the payment, either directly or through any Paying Agent (including an Issuer acting as its own Paying Agent) as the Trustee may determine, to the persons entitled thereto, of the principal and interest for whose payment such money has been deposited with or received by the Trustee or to make mandatory sinking fund payments or analogous payments as contemplated by Section 8.3 or 8.4.

 

(b)                                 The Issuers shall pay and shall indemnify the Trustee against any tax, fee or other charge imposed on or assessed against U.S. Government Obligations or Foreign Government Obligations deposited pursuant to Section 8.3 or 8.4 or the interest and principal received in respect of such obligations other than any payable by or on behalf of Holders.

 

(c)                                  The Trustee shall deliver or pay to the Issuers or the relevant Guarantor(s), as applicable, from time to time upon Issuer Request, any U.S. Government Obligations or Foreign Government Obligations or money held by it as provided in Section 8.3 or 8.4 which, in the opinion of a nationally recognized firm of independent certified public accountants expressed in a written certification thereof delivered to the Trustee, are then in excess of the amount thereof which then would have been required to be deposited for the purpose for which such U.S. Government Obligations or Foreign Government Obligations or money were deposited or received.  This provision shall not authorize the sale by the Trustee of any U.S. Government Obligations or Foreign Government Obligations held under this Indenture.

 

Section 8.3.                                 Legal Defeasance of Securities of any Series.

 

Unless this Section 8.3 is otherwise specified, pursuant to Section 2.2.25, to be inapplicable to Securities of any Series, the Issuers and each Guarantor shall be deemed to have paid and discharged the entire indebtedness on all the outstanding Securities of any Series on the 91st day after the date of the deposit referred to in subparagraph (d) hereof, and the provisions of this Indenture, as it relates to such outstanding Securities of such Series, shall no longer be in effect and any Guarantee will terminate with respect to that Series of Securities (and the Trustee, at the expense of the Issuers, shall, at Issuer Request, execute proper instruments acknowledging the same), except as to:

 

(a)                                 the rights of Holders of Securities of such Series to receive, from the trust funds described in subparagraph (d) hereof, (i) payment of the principal of and each

 

34

 

installment of principal of and interest on the outstanding Securities of such Series on the Stated Maturity of such principal or installment of principal or interest and (ii) the benefit of any mandatory sinking fund payments applicable to the Securities of such Series on the day on which such payments are due and payable in accordance with the terms of this Indenture and the Securities of such Series;

 

(b)                                 the provisions of Sections 2.4, 2.7, 2.8, 8.2, 8.3 and 8.5; and

 

(c)                                  the rights, powers, trust and immunities of the Trustee hereunder;

 

provided that, the following conditions shall have been satisfied:

 

(d)                                 the Issuers or, if applicable, any Guarantor(s) shall have deposited or caused to be irrevocably deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds in trust for the purpose of making the following payments, specifically pledged as security for, and dedicated solely to, the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent certified public accountants expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal of or interest, if any, on and any mandatory sinking fund payments in respect of all the Securities of such Series on the dates such installments of interest or principal and such sinking fund payments are due;

 

(e)                                  such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other material agreement or instrument to which an Issuer is a party or by which it is bound (other than a Default or Event of Default resulting from the borrowing of funds to be applied to such deposit (and any similar concurrent deposit related to other indebtedness of the Issuers or any Subsidiary) and the granting of liens to secure such borrowings);

 

(f)                                   no Default or Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit or during the period ending on the 91st day after such date;

 

(g)                                  the Issuers or, if applicable, any Guarantor(s), shall have delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel to the effect that (i) the Issuers or such Guarantor(s), as applicable, have received from, or there has been published by, the Internal Revenue Service a ruling, or (ii) since the date of execution of this Indenture, there has been a change in the applicable Federal income tax law, in either case to the effect that, and based thereon such Opinion of Counsel shall confirm that, the Holders of the Securities of such Series will not recognize income, gain or loss for

 

35

 

Federal income tax purposes as a result of such deposit, defeasance and discharge and will be subject to Federal income tax on the same amounts and in the same manner and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred;

 

(h)                                 the Issuers or, if applicable, any Guarantor(s), shall have delivered to the Trustee an Officers’ Certificate stating that the deposit was not made by the Issuers or such Guarantor(s), as applicable, with the intent of preferring the Holders of the Securities of such Series over any other creditors of the Issuers or with the intent of defeating, hindering, delaying or defrauding any other creditors of the Issuers or such Guarantor(s), as applicable; and

 

(i)                                     the Issuers or, if applicable, any Guarantor(s), shall have delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating to the defeasance contemplated by this Section have been complied with.

 

Section 8.4.                                 Covenant Defeasance.

 

Unless this Section 8.4 is otherwise specified pursuant to Section 2.2.25 to be inapplicable to Securities of any Series, the Issuers (and, if such Securities are subject to a Guarantee, the Guarantors thereof) may omit to comply with respect to the Securities of any Series with any term, provision or condition set forth under Sections 4.2, 4.3, 4.4, 4.5, and 5.1 as well as any additional covenants specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officers’ Certificate delivered pursuant to Section 2.2.25 (and the failure to comply with any such covenants shall not constitute a Default or Event of Default with respect to such Series under Section 6.1) and the occurrence of any event specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officers’ Certificate delivered pursuant to Section 2.2.18 and designated as an Event of Default shall not constitute a Default or Event of Default hereunder, with respect to the Securities of such Series, provided that the following conditions shall have been satisfied:

 

(a)                                 With reference to this Section 8.4, the Issuers or, if applicable, any Guarantor(s) have deposited or caused to be irrevocably deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds in trust for the purpose of making the following payments specifically pledged as security for, and dedicated solely to, the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and/or U.S. Government Obligations, or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and/or Foreign Government Obligations, which through the payment of interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent certified public accountants expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal of and or interest, if any, on and any

 

36

 

mandatory sinking fund payments in respect of all the Securities of such Series on the dates such installments of interest or principal and such sinking fund payments are due;

 

(b)                                 Such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other material agreement or instrument to which the Issuers are a party or by which it is bound (other than a Default or Event of Default resulting from the borrowing of funds to be applied to such deposit (and any similar concurrent deposit related to other indebtedness of the Issuers or any Subsidiary) and the granting of liens to secure such borrowings);

 

(c)                                  No Default or Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit;

 

(d)                                 The Issuers or, if applicable, the Guarantor(s) shall have delivered to the Trustee an Opinion of Counsel to the effect that Holders of the Securities of such Series will not recognize income, gain or loss for federal income tax purposes as a result of such deposit and covenant defeasance and will be subject to federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such deposit and covenant defeasance had not occurred; and

 

(e)                                  the Issuers or, if applicable, the Guarantor(s) shall have delivered to the Trustee an Officers’ Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the covenant defeasance contemplated by this Section have been complied with.

 

Section 8.5.                                 Repayment to Issuers.

 

The Trustee and the Paying Agent shall, prior to the applicable escheat date, pay to the Issuers (or, if applicable, the relevant Guarantor(s)) upon request any money held by them for the payment of principal and interest that remains unclaimed for two years and shall have no liability with respect to such funds upon payment thereof to the Issuers. After that, Securityholders entitled to the money must look solely to the Issuers (or, if applicable, the relevant Guarantor(s)) for payment as general creditors unless an applicable abandoned property law designates another person.

 

ARTICLE IX.
 AMENDMENTS AND WAIVERS

 

Section 9.1.                                 Without Consent of Holders.

 

The Issuers, the applicable Guarantor(s), if any, and the Trustee may amend or supplement this Indenture or the Securities of one or more Series without the consent of any Holder:

 

(a)                                 to cure any ambiguity, defect or inconsistency;

 

(b)                                 to comply with Article V;

 

37

 

(c)                                  to provide for uncertificated Securities in addition to or in place of certificated Securities;

 

(d)                                 to add guarantees with respect to Securities of any Series or secure Securities of any Series;

 

(e)                                  to surrender any of the Issuers’ rights or powers under this Indenture;

 

(f)                                   to add covenants or events of default for the benefit of the holders of Securities of any Series;

 

(g)                                  to comply with the applicable procedures of the applicable depository;

 

(h)                                 to make any change that does not materially adversely affect the rights of any Securityholder;

 

(i)                                     to provide for the issuance of and establish the form and terms and conditions of Securities of any Series and any Guarantees thereof, as permitted by this Indenture;

 

(j)                                    to evidence and provide for the acceptance of appointment hereunder by a successor Trustee with respect to the Securities of one or more Series and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee;

 

(k)                                 to conform the test of this Indenture, the Guarantees, if any, or the Securities to any provision of the final prospectus supplement filed with the SEC on the date of this Indenture;

 

(l)                                     to comply with requirements of the SEC in order to effect or maintain the qualification of this Indenture under the TIA;

 

(m)                             to comply with requirements of the SEC or changes to applicable law related to this Indenture, the Guarantees or the Securities;

 

(n)                                 to allow the Guarantor(s), if any to execute a supplemental indenture or Guarantee with respect to the Securities;

 

(o)                                 to reflect the release of the Guarantor in accordance with Article XII; or

 

(p)                                 to add guarantors with respect to any or all of the Securities or to secure any or all of the Securities or a Guarantee.

 

Section 9.2.                                 With Consent of Holders.

 

The Issuers, the applicable Guarantor(s), if any, and the Trustee may enter into a supplemental indenture with the written consent of the Holders of at least a majority in principal amount of the outstanding Securities of each Series affected by such supplemental indenture

 

38

 

(including consents obtained in connection with a tender offer or exchange offer for the Securities of such Series), for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner the rights of the Securityholders of each such Series.  Except as provided in Section 6.13, the Holders of at least a majority in principal amount of the outstanding Securities of any Series by notice to the Trustee (including consents obtained in connection with a tender offer or exchange offer for the Securities of such Series) may waive compliance by the Issuers or any Guarantor of Securities of such Series with any provision of this Indenture or the Securities or the applicable Guarantee with respect to such Series.

 

It shall not be necessary for the consent of the Holders of Securities under this Section 9.2 to approve the particular form of any proposed supplemental indenture or waiver, but it shall be sufficient if such consent approves the substance thereof.  After a supplemental indenture or waiver under this section becomes effective, the Issuers shall mail to the Holders of Securities affected thereby, a notice briefly describing the supplemental indenture or waiver.  Any failure by the Issuers to mail or publish such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture or waiver.

 

Section 9.3.                                 Limitations.

 

Without the consent of each Securityholder affected, an amendment or waiver may not:

 

(a)                                 reduce the principal amount of Securities whose Holders must consent to an amendment, supplement or waiver;

 

(b)                                 reduce the rate of or extend the time for payment of interest (including default interest) on any Security;

 

(c)                                  reduce the principal of or change the Stated Maturity of, any Security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation;

 

(d)                                 reduce the principal amount of Discount Securities payable upon acceleration of the maturity thereof;

 

(e)                                  waive a Default or Event of Default in the payment of the principal of or interest, if any, on any Security (except a rescission of acceleration of the Securities of any Series by the Holders of at least a majority in principal amount of the outstanding Securities of such Series and a waiver of the payment default that resulted from such acceleration);

 

(f)                                   make the principal of or interest, if any, on any Security payable in any currency other than that stated in the Security;

 

(g)                                  make any change in Section 6.8, 6.13 or 9.3 (this sentence);

 

(h)                                 waive a redemption payment with respect to any Security; or

 

39

 

(i)                                     if the Securities of that Series are entitled to the benefit of a Guarantee, release the Guarantor of such Series other than as provided in this Indenture or modify such Guarantee in any manner adverse to the Holders.

 

Section 9.4.                                 Compliance with Trust Indenture Act.

 

Every amendment to this Indenture or the Securities of one or more Series shall be set forth in a supplemental indenture hereto that complies with the TIA as then in effect.

 

Section 9.5.                                 Revocation and Effect of Consents.

 

Until an amendment is set forth in a supplemental indenture or a waiver becomes effective, a consent to it by a Holder of a Security is a continuing consent by the Holder and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder’s Security, even if notation of the consent is not made on any Security.  However, any such Holder or subsequent Holder may revoke the consent as to his Security or portion of a Security if the Trustee receives the notice of revocation before the date of the supplemental indenture or the date the waiver becomes effective.

 

Any amendment or waiver once effective shall bind every Securityholder of each Series affected by such amendment or waiver unless it is of the type described in any of clauses (a) through (h) of Section 9.3.  In that case, the amendment or waiver shall bind each Holder of a Security who has consented to it and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder’s Security.

 

Section 9.6.                                 Notation on or Exchange of Securities.

 

The Issuers or the Trustee may place an appropriate notation about an amendment or waiver on any Security of any Series thereafter authenticated.  The Issuers in exchange for Securities of that Series may issue and the Trustee shall authenticate, upon receipt of an Issuer Order, new Securities of that Series that reflect the amendment or waiver.

 

Section 9.7.                                 Trustee Protected.

 

In executing, or accepting the additional trusts created by, any supplemental indenture permitted by this Article or the modifications thereby of the trusts created by this Indenture, the Trustee shall be entitled to receive, and (subject to Section 7.1) shall be fully protected in conclusively relying upon, an Opinion of Counsel and an Officers’ Certificate stating that the execution of such supplemental indenture is authorized or permitted by this Indenture. The Trustee shall sign all supplemental indentures, except that the Trustee need not sign any supplemental indenture that adversely affects its rights or liabilities.

 

40

 

ARTICLE X.
 MISCELLANEOUS

 

Section 10.1.                          Trust Indenture Act Controls.

 

If any provision of this Indenture limits, qualifies, or conflicts with another provision which is required or deemed to be included in this Indenture by the TIA, such required or deemed provision shall control.

 

Section 10.2.                          Notices.

 

Any notice or communication by the Issuers, any Guarantor or the Trustee to the other, or by a Holder to the Issuers, such Guarantor or the Trustee, is duly given if in writing and delivered in person or mailed by first-class mail:

 

if to the Issuers or any Guarantor:

 

Communications Sales & Leasing, Inc.
 10802 Executive Center Drive,
 Benton Building Suite 300,
 Little Rock, AR 72211
 Attention: General Counsel
 Fax No.: (501) 537-0769

 

if to the Trustee:

 

[     ]
 Attention: [    ]
 Telephone: [    ]

 

with a copy to:

 

[     ]
 Attention: [    ]
 Telephone: [    ]

 

The Issuers, any Guarantor or the Trustee by notice to the others may designate additional or different addresses for subsequent notices or communications.

 

Any notice or communication to a Securityholder shall be mailed by first-class mail to his address shown on the register kept by the Registrar.  Failure to mail a notice or communication to a Securityholder of any Series or any defect in it shall not affect its sufficiency with respect to other Securityholders of that or any other Series.

 

If a notice or communication is mailed or published in the manner provided above, within the time prescribed, it is duly given, whether or not the Securityholder receives it. If a notice or communication is delivered in person, by courier or by facsimile transmission (with confirmation of receipt) within the time prescribed, it is duly given.

 

If the Issuers or any Guarantor mails a notice or communication to Securityholders, they shall mail a copy to the Trustee and each Agent at the same time.

 

41

 

Section 10.3.                          Communication by Holders with Other Holders.

 

Securityholders of any Series may communicate pursuant to TIA Section 312(b) with other Securityholders of that Series or any other Series with respect to their rights under this Indenture or the Securities of that Series or all Series.  The Issuers, the Trustee, the Registrar and anyone else shall have the protection of TIA Section 312(c).

 

Section 10.4.                          Certificate and Opinion as to Conditions Precedent.

 

Upon any request or application by the Issuers to the Trustee to take any action under this Indenture, the Issuers shall furnish to the Trustee:

 

(a)                                 an Officers’ Certificate stating that, in the opinion of the signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with; and

 

(b)                                 an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent have been complied with.

 

Section 10.5.                          Statements Required in Certificate or Opinion.

 

Each certificate or opinion with respect to compliance with a condition or covenant provided for in this Indenture (other than a certificate provided pursuant to TIA Section 314(a)(4)) shall comply with the provisions of TIA Section 314(e) and shall include:

 

(a)                                 a statement that the person making such certificate or opinion has read such covenant or condition;

 

(b)                                 a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based;

 

(c)                                  a statement that, in the opinion of such person, he has made such examination or investigation as is necessary to enable him to express an informed opinion as to whether or not such covenant or condition has been complied with; and

 

(d)                                 a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with.

 

Section 10.6.                          Rules by Trustee and Agents.

 

The Trustee may make reasonable rules for action by or a meeting of Securityholders of one or more Series.  Any Agent may make reasonable rules and set reasonable requirements for its functions.

 

Section 10.7.                          Legal Holidays.

 

A “Legal Holiday” is any day that is not a Business Day. If a payment date is a Legal Holiday at a place of payment, payment may be made at that place on the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the intervening period.

 

42

 

Section 10.8.                          No Recourse Against Others.

 

A director, officer, employee, partner or stockholder (past or present), as such, of the Issuers or any Guarantor shall not have any liability for any obligations of the Issuers or such Guarantor under the Securities, the Guarantee or this Indenture or for any claim based on, in respect of or by reason of such obligations or their creation.  Each Securityholder by accepting a Security waives and releases all such liability.  The waiver and release are part of the consideration for the issue of the Securities.

 

Section 10.9.                          Counterparts.

 

This Indenture may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.  The exchange of copies of this Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

 

Section 10.10.                   Governing Law.

 

THIS INDENTURE, THE SECURITIES AND EACH GUARANTEE, IF ANY, INCLUDING ANY CLAIM OR CONTROVERSY ARISING OUT OF OR RELATING TO THE INDENTURE OR THE SECURITIES, SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO CONFLICT OF LAW PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN THE LAW OF THE STATE OF NEW YORK.

 

Section 10.11.                   No Adverse Interpretation of Other Agreements.

 

This Indenture may not be used to interpret another indenture, loan or debt agreement of the Issuers, any Guarantor or any Subsidiary of the Company or of any Guarantor.  Any such indenture, loan or debt agreement may not be used to interpret this Indenture.

 

Section 10.12.                   Successors.

 

All agreements of the Issuers in, or of any Guarantor pursuant to, this Indenture and the Securities or Guarantee, as applicable, shall bind their respective successors.  All agreements of the Trustee in this Indenture shall bind its successor.

 

Section 10.13.                   Severability.

 

In case any provision in this Indenture or in the Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

43

 

Section 10.14.                   Table of Contents, Headings, Etc.

 

The Table of Contents, Cross-Reference Table, and headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof.

 

Section 10.15.                   Securities in a Foreign Currency.

 

Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officers’ Certificate delivered pursuant to Section 2.2 of this Indenture with respect to a particular Series of Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a specified percentage in aggregate principal amount of Securities of all Series or all Series affected by a particular action at the time outstanding and, at such time, there are outstanding Securities of any Series which are denominated in a coin or currency other than Dollars, then the principal amount of Securities of such Series which shall be deemed to be outstanding for the purpose of taking such action shall be that amount of Dollars that could be obtained for such amount at the Market Exchange Rate at such time. For purposes of this Section 10.15, “Market Exchange Rate” shall mean the noon Dollar buying rate in New York City for cable transfers of that currency as published by the Federal Reserve Bank of New York. If such Market Exchange Rate is not available for any reason with respect to such currency, the Trustee shall use, in its sole discretion and without liability on its part, such quotation of the Federal Reserve Bank of New York, as of the most recent available date, or quotations from one or more major banks in The City of New York or in the country of issue of the currency in question or such other quotations as the Trustee, upon consultation with the Issuers, shall deem appropriate. The provisions of this paragraph shall apply in determining the equivalent principal amount in respect of Securities of a Series denominated in currency other than Dollars in connection with any action taken by Holders of Securities pursuant to the terms of this Indenture.

 

All decisions and determinations of the Trustee regarding the Market Exchange Rate or any alternative determination provided for in the preceding paragraph shall be in its sole discretion and shall, in the absence of manifest error, to the extent permitted by law, be conclusive for all purposes and irrevocably binding upon the Issuers and all Holders.

 

Section 10.16.                   Judgment Currency.

 

The Issuers agree, to the fullest extent that they may effectively do so under applicable law, that (a) if for the purpose of obtaining judgment in any court it is necessary to convert the sum due in respect of the principal of or interest or other amount on the Securities of any Series (the “Required Currency”) into a currency in which a judgment will be rendered (the “Judgment Currency”), the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the day on which final unappealable judgment is entered, unless such day is not a New York Banking Day, then the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in The City of New York the Required Currency with the Judgment Currency on the New York Banking Day preceding the day on which final unappealable judgment is entered and (b) its obligations under this Indenture to make payments in the Required Currency (i) shall not be discharged or satisfied by any tender, any recovery pursuant to any judgment (whether or not entered in accordance with subsection (a)), in any currency other than the Required Currency, except to the extent that such

 

44

 

tender or recovery shall result in the actual receipt, by the payee, of the full amount of the Required Currency expressed to be payable in respect of such payments, (ii) shall be enforceable as an alternative or additional cause of action for the purpose of recovering in the Required Currency the amount, if any, by which such actual receipt shall fall short of the full amount of the Required Currency so expressed to be payable, and (iii) shall not be affected by judgment being obtained for any other sum due under this Indenture.  For purposes of the foregoing, “New York Banking Day” means any day except a Saturday, Sunday or a legal holiday in The City of New York on which banking institutions are authorized or required by law, regulation or executive order to close.

 

Section 10.17.      USA Patriot Act.

 

The parties hereto acknowledge that, in accordance with Section 326 of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (as amended, modified or supplemented from time to time, the “USA Patriot Act”), the Trustee, like all financial institutions, is required to obtain, verify, and record information that identifies each person or legal entity that opens an account. The parties to this Indenture agree that they will provide the Trustee with such information as the Trustee may reasonably request in order for the Trustee to satisfy the requirements of the USA Patriot Act.

 

Section 10.18.      Force Majeure.

 

In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances.

 

ARTICLE XI.
 SINKING FUNDS

 

Section 11.1.         Applicability of Article.

 

The provisions of this Article shall be applicable to any sinking fund for the retirement of the Securities of a Series, except as otherwise permitted or required by any form of Security of such Series issued pursuant to this Indenture.

 

The minimum amount of any sinking fund payment provided for by the terms of the Securities of any Series is herein referred to as a “mandatory sinking fund payment” and any other amount provided for by the terms of Securities of such Series is herein referred to as an “optional sinking fund payment.”  If provided for by the terms of Securities of any Series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 11.2.  Each sinking fund payment shall be applied to the redemption of Securities of any Series as provided for by the terms of the Securities of such Series.

 

45

 

Section 11.2.         Satisfaction of Sinking Fund Payments with Securities.

 

The Issuers may, in satisfaction of all or any part of any sinking fund payment with respect to the Securities of any Series to be made pursuant to the terms of such Securities (1) deliver outstanding Securities of such Series to which such sinking fund payment is applicable (other than any of such Securities previously called for mandatory sinking fund redemption) and (2) apply as credit Securities of such Series to which such sinking fund payment is applicable and which have been repurchased by the Issuers or redeemed either at the election of the Issuers pursuant to the terms of such Series of Securities (except pursuant to any mandatory sinking fund) or through the application of permitted optional sinking fund payments or other optional redemptions pursuant to the terms of such Securities, provided that such Securities have not been previously so credited.  Such Securities shall be received by the Trustee, together with an Officers’ Certificate with respect thereto, not later than 15 days prior to the date on which the Trustee begins the process of selecting Securities for redemption, and shall be credited for such purpose by the Trustee at the price specified in such Securities for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced accordingly.  If as a result of the delivery or credit of Securities in lieu of cash payments pursuant to this Section 11.2, the principal amount of Securities of such Series to be redeemed in order to exhaust the aforesaid cash payment shall be less than $100,000, the Trustee need not call Securities of such Series for redemption, except upon receipt of an Issuer Order that such action be taken, and such cash payment shall be held by the Trustee or a Paying Agent and applied to the next succeeding sinking fund payment, provided, however, that the Trustee or such Paying Agent shall from time to time upon receipt of an Issuer Order pay over and deliver to the Issuers any cash payment so being held by the Trustee or such Paying Agent upon delivery by the Issuers to the Trustee of Securities of that Series purchased by the Issuers having an unpaid principal amount equal to the cash payment required to be released to the Issuers.

 

46

 

Section 11.3.         Redemption of Securities for Sinking Fund.

 

Not less than 45 days (unless otherwise indicated in the Board Resolution, supplemental indenture hereto or Officers’ Certificate in respect of a particular Series of Securities) prior to each sinking fund payment date for any Series of Securities, the Issuers will deliver to the Trustee an Officers’ Certificate specifying the amount of the next ensuing mandatory sinking fund payment for that Series pursuant to the terms of that Series, the portion thereof, if any, which is to be satisfied by payment of cash and the portion thereof, if any, which is to be satisfied by delivering and crediting of Securities of that Series pursuant to Section 11.2, and the optional amount, if any, to be added in cash to the next ensuing mandatory sinking fund payment, and the Issuers shall thereupon be obligated to pay the amount therein specified.  Not less than 30 days (unless otherwise indicated in the Board Resolution, Officers’ Certificate or supplemental indenture in respect of a particular Series of Securities) before each such sinking fund payment date the Trustee shall select the Securities to be redeemed upon such sinking fund payment date in the manner specified in Section 3.2 and cause notice of the redemption thereof to be given in the name of and at the expense of the Issuers in the manner provided in Section 3.3.  Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Sections 3.4, 3.5 and 3.6.

 

ARTICLE XII.
 GUARANTEES

 

Section 12.1.         Guarantees.

 

Any Series of Securities may be guaranteed by one or more Guarantors.  The terms and the form of any such Guarantee shall be established in the manner contemplated by Section 2.2 hereof for such Series of Securities; provided, however, that, prior to the authentication and delivery upon original issuance of any Series of Securities that are to be so guaranteed, the Issuers and the Trustee and each person that shall be an initial Guarantor of such Series of Securities shall execute and deliver a supplemental indenture hereto pursuant to Section 9.1 hereof, whereby such person shall become a Guarantor under this Indenture with respect to such Series of Securities.

 

[SIGNATURE PAGE FOLLOWS]

 

47

 

IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the day and year first above written.

 

	
 
    	
Communications   Sales & Leasing, Inc.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Its:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
CSL Capital, LLC
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Its:
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
                           ,   as Trustee
    
	
 
    	
 
    
	
 
    	
By:
    	
 
    
	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
Its:Exhibit 10.2 Master Services Agreement

Confidential to Diabesity Inc. and BioFocus

MASTER RESEARCH SERVICES AGREEMENT

This Research Services Agreement is made on July 15, 2014 (“Effective Date”)

BETWEEN:

(1)

BioFocus DPI Limited a company incorporated under the laws of England and Wales (under company registration number 4622227) whose registered address is at Charles River, Manston Road, Margate, Kent, CT9, United Kingdom and whose principal place of business is at Chesterford Research Park, Saffron Walden, Essex CB10 1XL, United Kingdom

Hereafter referred to as “BioFocus”

and

(2)

Diabesity Inc a company incorporated under the laws of Delaware (under company registration number SRV 130450721 - 5321386) whose registered address is at 8 Hillside Avenue, Suite 207, Montclair, NJ 07042

Hereafter referred to as “Client”

WHEREAS

(A)

BioFocus possesses or has access to a library of compounds and has developed and continues to develop certain techniques, know-how, experience and intellectual property that are relevant to drug discovery and development activities (including assay development, structural biology, compound selection, high throughput screening, and computational, synthetic and medicinal chemistry). 

(B)

The Client wishes to engage BioFocus to perform certain research services, that will be described in one or more Schedules of Work to be agreed by the Parties from time to time, and BioFocus is willing to provide such services, in accordance with the provisions of this agreement.

The Parties AGREE AS FOLLOWS:

1.

Definitions

In this agreement, the following words have the following meanings:

		
	Affiliate

	In relation to a Party, any entity or person which Controls, is Controlled by, or is under common Control with that Party;

 

	Background Intellectual Property

	Any and all Intellectual Property in either Party’s ownership, possession or control prior to the Effective Date or generated outside of this agreement after the Effective Date;

 

	BioFocus Compounds

	Any compound owned, controlled or commercially available and supplied by BioFocus for the performance of the Services, whether or not any such compound exists in any library owned or controlled by BioFocus;

 

	BioFocus Indemnitees

	Has the meaning given in Clause 6.3;

 

	BioFocus Methodologies

	(i) Any and all general methods, processes, techniques, synthesis routes and other know-how within BioFocus’ Background Intellectual Property used by BioFocus, or any of its Affiliates, in the performance of the Services, and/or (ii) any know-how generated by BioFocus or such Affiliate during the performance of the Services that constitutes an improvement, modification or enhancement of the subject matter (i) above but that makes no reference to or use of the Client’s Confidential Information, Delivered Items, New Intellectual Property, Results and/or Client Materials;

 

	Claims

	Has the meaning given in Clause 6.4.1;

 

	Client Indemnitees

	Has the meaning given in Clause 6.4;

 

	Client’s Permitted Collaborator

	Any third party chosen by the Client to undertake further research and development of the Results;

 

Page 1 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

		
	Client Materials

	Any and all information, data and materials in whatever form or format, including any compounds and/or any biological, chemical or other materials and/or structures (whether or not owned, controlled, or commercially available) disclosed to or provided by the Client to BioFocus for the performance of the Services; 

 

	Confidential Information

	Means all confidential or proprietary information, data or materials in whatever form or format, including but not limited to amino or nucleic acid sequences, probes, cDNA libraries, plasmids, vectors, expression systems, cells, cell lines, organisms, antibodies, biological substances and any constituents, progeny, mutants, derivatives or replications thereof or therefrom, together with all reagents, chemical compounds, targets and other information concerning methods of operations, processes, formulations, reports, know-how, business plans, costs, sales and research, proposals and any record-bearing media containing or disclosing such information;

 

	Control

	Direct or indirect beneficial ownership or management control of 50% (or, outside a Party’s home territory, such lesser percentage as is the maximum permitted level of foreign investment) or more of the share capital, stock or other participating interest carrying the right to vote or to distribution of profits of that entity or person, as the case may be; and “Controls” and “Controlled” shall be interpreted accordingly;

 

	Delivered Items

	Any reports, recommendations, data, Results or materials generated by BioFocus for the Client in the performance of the Services in accordance with a Schedule of Work;

 

	Disclosing Party

	Has the meaning given in Clause 5.1; 

 

	Effective Date

	Has the meaning given above;

 

	FTE

	Means an amount of resource equivalent to that applied by one full time employee of BioFocus in one year, which shall be deemed to be 1650 hours of resource; 

 

	FTE Rates

	Means the price payable per FTE per annum pro rata, the price being dependent on the FTE’s scientific discipline;

 

	Hit Compound

	Any compound or other chemical or biological material that is identified as a direct result of the provision of the Services as having positive and desired activity when screened in an assay as specified in Section 4.2 of the Schedule of Work; 

 

	Indemnifying Party

	Has the meaning given in Clause 6.4.2;

 

	Intellectual Property

	All patents, rights to inventions, database rights, copyright and related rights, trade marks, rights in designs, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications for and renewals or extensions of such rights, and all similar or equivalent rights or forms of protection in any part of the world;

 

	Licensed Product

	Any pharmaceutical composition that includes a Hit Compound or a Novel Client Compound (as applicable), or any analogue or derivative of a Hit Compound or Novel Client Compound generated by the Client or its licensee or assignee;

 

	New Intellectual Property

	Any and all Intellectual Property generated by BioFocus as a direct consequence of performing the Services and/or arising directly pursuant to the objectives under any Schedule of Work but excluding any Intellectual Property so generated that is part of BioFocus Methodologies;

 

	Novel Client Compound

	Any compound or other chemical or biological material and those with close structural and chemical similarity that is (a) created as a direct result of the provision of the Services; (b) not a BioFocus Compound; and (c) novel, as determined by BioFocus to the best of its knowledge; 

 

	Parties

	BioFocus and the Client. ‘Party’ shall mean either of them;

 

	Project Management Committee

	A committee formed and operating in accordance with Clause 2.2;

 

Page 2 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

		
	Receiving Party

	Has the meaning given in Clause 5.1;

 

	Research Fees

	Has the meaning given in Clause 3.1.1;

 

	Results

	Chemical, biological and other data and information in respect of any Hit Compounds, Client Materials and/or Novel Client Compounds, and chemical synthetic methods relating solely to Novel Client Compounds, generated by BioFocus as a direct consequence of performing the Services, but excluding all BioFocus Background Intellectual Property and any Intellectual Property in BioFocus Methodologies; 

 

	Schedule of Work

	A document which sets out the Services and the respective obligations of the Parties related to the Services, which is agreed in writing by the Parties, references this agreement and thereby forms an integral part of this agreement. During the term of this agreement, one or more Schedules of Work can be entered into; and 

 

	Services

	The services to be performed by BioFocus as specifically detailed in each Schedule of Work.

 

	Specific Use

	Means inhibition of Fyn kinase. 

2.

Research and development

2.1

Obligations and Services

2.1.1

BioFocus and the Client shall perform their respective duties as set out in each Schedule of Work but nothing in this agreement obligates the Parties to enter into any Schedule of Work. Each Party expressly acknowledges that the purpose of this agreement is to carry out experimental research and accordingly, specific results cannot be guaranteed. Nothing in this agreement nor in the Schedules of Work should be interpreted to the contrary.

2.1.2

Each Party shall carry out its respective obligations as set out in each Schedule of Work in accordance with all applicable laws, rules and regulations in the country or countries in which those obligations are being performed.

2.1.3

If the Client wishes to change the Services described in a Schedule of Work, or wishes to obtain additional Services not initially covered by a Schedule of Work, then the Client will need to make a written request to BioFocus. If the requested modifications or the extension of the Services is acceptable to BioFocus, as determined by BioFocus in its sole discretion, BioFocus will submit to the Client either a new written Schedule of Work or an amendment to the existing Schedule of Work, for the Client’s approval. BioFocus shall not unreasonably withhold its agreement to the requested modifications or extensions. No such Client request is binding until the Parties agree to it in signed writing in either of the formats specified above. Such signed document will form an integral part of the relevant Schedule of Work. 

2.1.4

BioFocus shall use reasonable efforts to respect the timelines estimated in the relevant Schedule of Work for the performance of the Services. If delays are encountered versus these timelines, BioFocus shall notify the Client and both Parties shall discuss in good faith how to address such delays. 

2.2

Records, meetings and reports

2.2.1

BioFocus shall maintain complete and accurate records of its activities as set out in each Schedule of Work.

2.2.2

BioFocus and the Client shall, where appropriate, establish a Project Management Committee upon signature of each Schedule of Work. Where applicable, the Project Management Committee shall:

(a)

comprise equal numbers of representatives of each Party, the numbers to be agreed but should be no more than 3 representatives nominated from time to time by BioFocus, including the BioFocus Project Manager (identified in the Schedule of Work), and no more than 3 representatives nominated from time to time by the Client, including the Client Project Manager for the relevant Services (as identified in the corresponding Schedule of Work); 

(b)

meet periodically (and in any event at least quarterly) and confer by telephone or video conference to review and discuss the progress and direction of each Schedule of Work;

(c)

advise the Parties generally on the conduct and progress of the performance of the Services; and

Page 3 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

(d)

prepare and propose to the Parties any amendments or supplements to each Schedule of Work, including any changes to FTE allocations and whether any extraordinary costs are or should be incurred and charged to the Client (e.g. for reagents).

2.2.3

In addition to formal Project Management Committee meetings, telephone conferences and video conferences, the Parties shall maintain an informal, interactive dialogue throughout the course of each Schedule of Work.

2.2.4

Unless otherwise specified in the relevant Schedule of Work, BioFocus shall prepare and send to the Client written reports according to the relevant Schedule of Work and within 90 days of the completion or termination of the Services specified in each Schedule of Work. The reports will describe the progress made in respect of each Schedule of Work and set forth the Results of Services carried out as set out in each Schedule of Work.

2.3

Subcontracting

2.3.1

BioFocus may elect to subcontract any part of the Services to any of its Affiliates without having to obtain consent from the Client provided that:

(a)

such subcontracted Services are agreed in the relevant Schedule of Work; and 

(b)

such Services are performed in accordance with this agreement and the relevant Schedule of Work; and 

(c)

BioFocus shall remain fully responsible to the Client for the performance of such Services by its Affiliate. 

2.3.2

The Parties further agree that in the event that BioFocus subcontracts any part of the Services to an Affiliate, invoices for such Services may be issued to the Client direct by the relevant Affiliate in the currency specified in the relevant Schedule of Work or as otherwise agreed in writing between the Parties. The Client shall pay such invoices directly to the relevant Affiliate and such payment will fulfil the payment obligation of the Client to BioFocus under this agreement in respect of such subcontracted Services.

3.

Payments

3.1

Research Fees

3.1.1

In consideration of BioFocus performing the Services, the Client shall pay to BioFocus the amounts described or referred to in the relevant Schedule of Work, in accordance with the provisions of that Schedule of Work (“Research Fees”).

3.1.2

BioFocus may elect to increase the Research Fees, including any FTE Rates, once in any 12-month period. BioFocus shall give the Client not less than one (1) months’ notice of any increase in the Research Fees. Any such increase should not exceed the percentage increase, over the last 12 months for which figures are available, in the UK All Items Retail Prices Index. Any increase in the Research Fees will apply with effect from the expiry of BioFocus’ notice.

3.2

Expenses and consumables

3.2.1

The Client shall reimburse to BioFocus, in addition to the Research Fees, the cost of hotel, subsistence, travelling and other ancillary expenses reasonably and properly incurred by BioFocus employees, subcontractors and agents in the provision of the Services, unless otherwise agreed in the relevant Schedule of Work. BioFocus will submit any invoices for expenses to the Client monthly in arrears and such invoices are payable by the Client in accordance with Clause 3.4.

3.2.2

The Client shall reimburse to BioFocus, in addition to the Research Fees, the cost of any consumables purchased by BioFocus on behalf of the Client necessary for the performance of the Services, unless otherwise agreed in the relevant Schedule of Work. Such consumables will be itemised in the relevant Schedule of Work and agreed between the Parties. BioFocus will submit any invoices for consumables monthly in arrears (unless otherwise agreed in the Schedule of Work) and such invoices are payable by the Client in accordance with Clause 3.4. 

3.3

Milestone and royalty payments

Where applicable, the Client shall pay to BioFocus the success fees, milestone payments, royalties and other payments described in that Schedule of Work. 

Page 4 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

Any such payments due under a Schedule of Work are payable to BioFocus by the Client within 30 days of such payment becoming due.

3.4

Payment terms

Subject to 2.3.2, all sums payable by the Client to BioFocus under this agreement:

(a)

are to be paid in United States Dollars (USD) (without deduction for bank charges or currency exchange) by direct credit transfer to a bank account nominated by BioFocus, or by such other method as BioFocus may reasonably require; and

(b)

are to be paid within 30 days of receipt of a proper invoice, failing which BioFocus may charge interest on any outstanding amount on a daily basis at a rate equivalent to 8% above the Bank of England base lending rate then in force in London;

(c)

are exclusive of VAT, sales tax, or any other applicable tax, which (if and when applicable) will be paid by the Client to BioFocus over and above the Research Fees; 

(d)

are to be made without deduction of income tax or other taxes, charges or duties that may be imposed, except in so far as the Client is required to deduct such charges to comply with applicable laws. The Parties shall cooperate and take all steps reasonably and lawfully available to them, to avoid deducting such taxes and to obtain double taxation relief. If the Client is required to make any such deduction it shall provide BioFocus with such certificates or other documents as it can reasonably obtain to enable BioFocus to obtain appropriate relief from double taxation of the payment in question.

3.5

Shipping Costs

All shipping costs (including insurance and importation costs) in connection with the performance of the Services under any Schedule of Work are to be borne by the Client.

4.

Intellectual Property

4.1

Background IP 

4.1.1

Nothing in this agreement affects:

(a)

a Party’s ownership of, and rights to, its Background Intellectual Property; or

(b)

BioFocus’ ownership of, and rights to, BioFocus Compounds; or

(c)

Client’s ownership of, and rights to, Client Materials; or 

(d)

where applicable, a third party’s ownership of any BioFocus Compounds or Client Materials used in the provision of the Services.

4.1.2

During the Term, the Client grants to BioFocus a royalty-free, fully paid-up, worldwide, non-exclusive license to use the Client’s Background Intellectual Property, solely to the extent necessary for BioFocus to perform the Services.

4.2

Results 

Upon completion of each Schedule of Work and full payment by the Client to BioFocus of all amounts due under the relevant Schedule of Work, BioFocus shall, in so far as it has the legal right to do so:

4.2.1

assign to the Client all of BioFocus’ right, title and interest in New Intellectual Property, including any Delivered Items and Novel Client Compounds, save that New Intellectual Property shall not include any BioFocus Methodologies.

Page 5 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

4.2.2

grant the Client, a non-exclusive, royalty-free, fully paid-up, worldwide, perpetual license to use the Hit Compounds (where such Hit Compound arises from a BioFocus Compound), and any of BioFocus’ Background Intellectual Property specifically used in the performance of the Services and necessary for development of the Results, solely for the Client’s or the Client’s Permitted Collaborator’s own research and development purposes with respect to Hit Compounds and/or for the purpose of undertaking research, developing, making, having made, using, keeping, importing and exporting (as required) and selling Licensed Products.

4.2.3

grant to the Client, BioFocus’ right to file and have granted one or more patents to any Novel Client Compounds and subject to Clause 4.3.3 below and where applicable, the right to file and have granted one or more patents to the Specific Use of any Hit Compound that is not a Client Compound.

4.3

Reserved rights 

4.3.1

As between the Parties, full title to any Intellectual Property arising and generated in the provision of the Services in respect of BioFocus Compounds, BioFocus Methodologies and Hit Compounds (solely to the extent such Hit Compounds are BioFocus Compounds) remains with BioFocus, subject to the licence granted in Clause 4.2.

4.3.2

As between the Parties, full title to any Intellectual Property (including New Intellectual Property) arising and generated in the provision of the Services in respect of Client Materials shall be the property of Client.

4.3.3

Nothing in this agreement prevents BioFocus from carrying out synthetic and medicinal chemistry services, screening services or other research services for any other person, including any services that use the same or a similar compound library to any library used to perform the Services under this agreement, provided that such services will not conflict with the provision of Services under this agreement. BioFocus will not use any Confidential Information of the Client in providing such services.

4.3.4

The Client shall not sell any BioFocus Compounds nor make them available to any other person, or incorporate any of them into any other product or file for a patent application or any other form of registered right containing the same other than specifically provided for under Clause 4.2.3, without the prior written agreement of BioFocus.

4.3.5

Except for the licences and assignments expressly provided for under this agreement, each Party reserves all its rights.

4.4

Third party rights 

BioFocus warrants that it will not knowingly infringe any third party’s Intellectual Property rights in the performance of the Services, but where the Services require the use of commercially available compounds, Client Materials, or a target which has been specifically requested by the Client, the Client agrees that BioFocus has no liability to the Client in respect of any infringement or alleged infringement of third party Intellectual Property rights. In such circumstances, the Client shall be solely responsible for dealing with any such infringement or alleged infringement, and obtaining any necessary licences, consents or permits from third parties, at its sole cost and expense.

4.5

Patent filings

The Client shall be solely responsible for filing and prosecuting patent applications (at its discretion) in respect of Novel Client Compounds, Results and New Intellectual Property that has been assigned to the Client under Clause 4.2.1, and in respect of Hit Compounds (which are BioFocus Compounds) under Clause 4.2.3 at the Client’s sole cost and expense. BioFocus shall execute such documents as the Client may reasonably require with respect to any such applications, and take such other actions as the Client may reasonably request in order to obtain and maintain such patents. However, the Parties agree that BioFocus will be at liberty to charge the Client for all labour costs at the rate of USD 1,250 per day (on a pro rata basis) and other expenses incurred by BioFocus in fulfilling its obligations under this Clause 4.5. 

4.6

Abandoning the patents

If the Client does not wish to apply for, or at any stage continue with, or bear any costs of, patent protection in respect of Novel Client Compounds it shall give BioFocus the opportunity to do so at no cost but at BioFocus’ sole expense, and shall assign all its right, title and interest in such patents and applications to BioFocus. Thereafter the Client has no rights in such application or patents.

Page 6 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

5.

Confidential Information

5.1

Each Party (“Receiving Party”) shall:

5.1.1

maintain in confidence any Confidential Information provided to it directly or indirectly by the other Party (‘Disclosing Party’) during, or in anticipation of, this agreement, taking such reasonable security measures as it takes to protect its own confidential information and trade secrets;

5.1.2

use such Confidential Information only for the purposes of carrying out the Schedule(s) of Work or as may be licensed or permitted under Clause 4; 

5.1.3

not disclose such Confidential Information to any other person, other than to employees, consultants, officers, licensees or potential licensees who (in each case) have accepted obligations of confidentiality and non-use equivalent to the provisions of this Clause 5 and who need to have access to such Confidential Information in connection with the performance of this agreement or for the exercise of rights under Clause 4.

5.2

The obligations set out in Clause 5.1 do not apply to any Confidential Information received by a Party that can prove by written records:

5.2.1

(except where BioFocus is the Receiving Party with respect to new Intellectual Property and Results) was already in the Receiving Party’s property or lawfully in its possession prior to receiving it from the other Party; or

5.2.2

is subsequently generated by the Receiving Party without the use of, or reliance upon, any Confidential Information of the Disclosing Party; or

5.2.3

was already in the public domain when it was provided by the Disclosing Party; or

5.2.4

subsequently enters the public domain through no fault of the Receiving Party; or

5.2.5

is received from a third party who has the lawful right to provide it to the Receiving Party without imposing obligations of confidentiality; or

5.2.6

is being disclosed to a government agency for review in connection with an application by a Party or its licensee for the testing or commercialisation of a compound. However, such disclosures should be made in confidence wherever such agency’s procedures permit it to receive such information in confidence; or

5.2.7

is required to be disclosed by an order of any court of competent jurisdiction or governmental authority, or by the requirements of any stock exchange on which the shares of the Receiving Party are listed or are to be listed, provided that reasonable efforts are used by the Receiving Party to secure a protective order or equivalent over such information and provided further that the Disclosing Party is informed as soon as possible and be given an opportunity, if time permits, to make appropriate representations to such court, authority or stock exchange to attempt to secure that the information is kept confidential.

5.3

The provisions of this Clause 5 survive any termination of this agreement for a period of seven (7) years.

5.4

Notwithstanding the obligations set forth above in this Clause 5, BioFocus may disclose any Confidential Information to its Affiliate(s) according to and for the sole purpose described in Clause 2.3. Such Affiliate(s) shall be bound by obligations of confidentiality equivalent to those imposed on BioFocus as set forth within this Clause 5.

Page 7 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

6.

Warranties, liabilities and indemnities

6.1

Experimental research

The Parties acknowledge that this agreement is to carry out experimental research and for the use of experimental materials whose properties and safety may not have been established. Accordingly specific results cannot be guaranteed and any Delivered Items provided by BioFocus to the Client under this agreement are provided ‘as is’ and without any express or implied warranties, representations or undertakings. As examples, but without limiting the foregoing, BioFocus does not give any warranty that Delivered Items do not infringe third party rights, are of merchantable or satisfactory quality, are fit for any particular purpose, comply with any sample or description, or are viable, uncontaminated, safe or non-toxic, nor that any patent applications made or licensed pursuant to this agreement will result in valid, granted patents. BioFocus does not give any warranty that any Hit Compounds or Novel Client Compounds will be identified in the provision of the Services nor that quantities of any Hit Compounds or Novel Client Compounds will be available from BioFocus or any third party.

6.2

No other warranties

Each of the Parties acknowledges that, in entering into this agreement, it does not do so in reliance on any representation, warranty or other provision except as expressly provided in this agreement, and any conditions, warranties or other terms implied by statute or common law are excluded from this agreement to the fullest extent permitted by law.

6.3.

Indemnification 

BioFocus shall indemnify, defend and hold harmless the Client, its Affiliates, and their respective officers, directors, employees, consultants, agents and representatives (the ‘Client Indemnitees’) against all third party Claims which may be asserted against or suffered by any of the Client Indemnitees arising out of or in connection with BioFocus’ knowing breach of third party Intellectual Property rights in its performance of the Services and/or any deliberate breach of its confidentiality obligations under section 5 of this Agreement , provided however that BioFocus shall not indemnify any Client Indemnitee to the extent the Claim is caused by (a) the gross negligence or wilful misconduct of the Client, or (b) the material failure of the Client to comply with the terms of this agreement. 

The Client shall indemnify, defend and hold harmless BioFocus, its Affiliates, and their respective officers, directors, employees, consultants, agents and representatives (the ‘BioFocus Indemnitees’) against all third party Claims which may be asserted against or suffered by any of the BioFocus Indemnitees and which relate to the Client’s use of the Delivered Items and/or the development, manufacture, distribution, sale, supply and/or use of any products or services which incorporate any Delivered Items, provided however that the Client shall not indemnify BioFocus to the extent the Claim is caused by (a) the gross negligence or wilful misconduct of BioFocus, or (b) the material failure of BioFocus to comply with the terms of this agreement. 

6.4

Meaning and conduct of Claims

6.4.1

As used in this Clause 6, ‘Claims’ means all demands, claims and liability (whether criminal or civil, in contract, tort or otherwise) for losses, damages, reasonable legal costs and other expenses of any nature whatsoever and all reasonable costs and expenses (including without limitation legal costs) incurred in connection therewith.

6.4.2

A Client Indemnitee or BioFocus Indemnitee (“Indemnitee”) seeking indemnification pursuant to this Clause 6 shall provide prompt written notice to BioFocus or Client, as applicable (the “Indemnifying Party”); of its intent to initiate any action or proceeding that may reasonably lead to a claim for indemnification. Upon such notice, the Indemnifying Party has the right to assume the defence and settlement of such action or proceeding, provided that it shall not settle any action or proceeding without the other Party’s written consent. Neither Party will unreasonably withhold its approval with the settlement of the Claim. Any Party shall cooperate with the other Party in the investigation and/or defence of such Claim. The Indemnitee shall not make any admission in respect of such Claim prejudicial to the defence of it without the prior written consent of the Indemnifying Party. The Indemnifying Party is not obligated to indemnify the Indemnitee for any settlement or other payment of costs or expenses incurred in connection with the defence and the settlement without the written consent of the Indemnifying Party.

Page 8 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

6.5

Limitation of liability

6.5.1

To the extent permitted by law, and in circumstances where BioFocus has not effectively excluded liability to the Client under or in connection with this agreement, the maximum aggregate liability of BioFocus to the Client in relation to each Schedule of Work, whether in contract, tort, negligence, breach of statutory duty or otherwise, is limited to an amount not exceeding the price paid by the Client to BioFocus under the Schedule of Work such liability is alleged to arise from or is connected with. Nothing in this Agreement shall exclude the liability of BioFocus for death or personal injury caused by its negligence, in respect of fraudulent misrepresentation or any other liability that cannot be excluded or restricted by law.

6.6

Exclusion of liability

Notwithstanding any other provision of this agreement, to the extent permitted by law BioFocus is not liable to the Client (in contract, tort, negligence, breach of statutory duty or otherwise) for any loss of turnover, profits, business or goodwill, or for any loss, damage, costs or expenses of any nature whatsoever incurred or suffered by the Client that is of an indirect or consequential nature.

7.

Duration and termination

7.1

Commencement and termination by expiry 

This agreement comes into effect on the Effective Date and, unless terminated earlier in accordance with this Clause 7, continues in force until the fifth anniversary of the Effective Date (unless extended by written agreement of the Parties); and on such date this agreement will terminate automatically by expiry. Expiration of this agreement shall not terminate any Schedule of Work then in place, which shall continue under the terms of the agreement.

7.2

Early termination

7.2.1

Either Party has the right to terminate this agreement for convenience and/or any Schedule of Work at any time on 90 days’ notice in writing to the other Party. Any Schedules of Work ongoing at the time shall not be terminated and shall only terminate on completion of all Services thereunder by BioFocus.

7.2.2

Without prejudice to any other right or remedy, either Party has the right to terminate this agreement and/or any Schedule of Work at any time:

(a)

with immediate effect if the other Party materially breaches this agreement and such other Party has not remedied the breach within 60 days after receipt of the written notice specifying the nature of the breach; or

(b)

with immediate effect if the other Party becomes insolvent, or if an order is made or a resolution is passed for the winding up of the other Party (other than voluntarily for the purpose of solvent amalgamation or reconstruction), or if an administrator, administrative receiver or receiver is appointed in respect of the whole or any part of the other Party's assets or business, or if the other Party makes any composition with its creditors or takes or suffers any similar or analogous action in consequence of debt.

7.3

Consequences of termination

7.3.1

Upon expiration or termination of this agreement, the Receiving Party shall, upon request of the Disclosing Party, return to the Disclosing Party all documents, and copies thereof, containing the Disclosing Party’s Confidential Information and make no further use of such Confidential Information. However, the Receiving Party may retain one copy of such documents in a secure location solely to determine its obligations under Clauses 5 and 7;

7.3.2

In the event of termination of this agreement and/or any Schedule of Work by the Client according to Clause 7.2.1, or in the event of termination by BioFocus in the event of Clause 7.2.2 (a) or 7.2.2 (b), and Services under one or more Schedules of Work are on-going at the date of termination, the Client shall pay BioFocus for all Services performed, and all costs and expenses incurred, by BioFocus up to the point of termination including any reasonably incurred non-cancellable expenses in anticipation of completion of the Schedule of Work by BioFocus, less the amounts already paid by Client.  

Page 9 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

7.3.3

In the event of termination of this agreement and/or any Schedule of Work, BioFocus shall, upon payment of all fees due to it under this agreement, (a) deliver any items that BioFocus is required to provide to the Client as described in each Schedule of Work, and reports not previously delivered to the Client in such condition as they are in as at the date of termination; and (b) assign the rights in accordance with Clause 4.2.1 and grant the rights in accordance with Clause 4.2.2 - 4.2.3. 

7.3.4

Notwithstanding the expiration or termination of this agreement, the provisions of Clauses 1, 3, 4 (subject to Clause 7.3.3), 5, 6 and 7.3 shall continue in full force and effect; and

7.3.5

Subject to as provided in this Clause 7.3, and except in respect of any accrued rights, upon expiration or termination of this agreement, neither Party shall be under any further obligation to the other.

8.

General

8.1

Force majeure

Neither Party has any liability or is be deemed to be in breach of this agreement or any Schedule of Work for any delays or failures in performance which result from circumstances beyond the reasonable control of that Party, including without limitation labour disputes involving that Party. The Party affected by such circumstances shall promptly notify the other Party in writing when such circumstances cause a delay or failure in performance and when they cease to do so.

8.2

Amendment

This agreement must only be amended in writing signed by duly authorised representatives of BioFocus and the Client.

8.3

Assignment

8.3.1

This agreement and each Schedule of Work shall be binding upon and inure to the benefit of the successors in interest of each respective Party. Neither Party is permitted to assign, mortgage, charge or otherwise transfer any rights or obligations under this agreement or any Schedule of Work without the prior written consent of the other Party. However, either Party may, without such consent, assign all its rights and obligations under this agreement and each schedule of Work to any third party to which it transfers all or part of its assets or business to which this agreement and that (those) Schedule(s) of Work relate, provided that the assignee undertakes to the other Party to be bound by and perform the obligations of the assignor under this agreement.

8.3.2

Notwithstanding Clause 8.3.1, BioFocus is permitted to transfer or assign this agreement, without the prior consent of the Client, to any of its Affiliates so long as (a) it also assigns all Schedules of Work to the same Affiliate and (b) the Affiliate expressly assumes all of the obligations of BioFocus.

8.4

Waiver

No failure or delay on the part of either Party to exercise any right or remedy under this agreement or a Schedule of Work will be construed or operate as a waiver of such right or remedy, nor will any single or partial exercise of any right or remedy preclude the further exercise of such right or remedy.

8.5

Severability 

8.5.1

If any provision of this agreement or a Schedule of Work is or becomes illegal, invalid or unenforceable in any jurisdiction, that does not affect:

(a)

the legality, validity or enforceability in that jurisdiction of any other provision of this agreement or the relevant Schedule of Work; or

(b)

the legality, validity or enforceability in any other jurisdiction of that or any other provision of this agreement or the relevant Schedule of Work.

8.5.2

Whilst the Parties consider the provisions contained in this agreement reasonable, having taken independent legal advice, if any one or more of the provisions are adjudged alone or together to be illegal, invalid or unenforceable, the Parties shall negotiate in good faith to modify any such provision(s) so that to the greatest extent possible they achieve the same effect as would have been achieved by the invalid or unenforceable provision(s). 

Page 10 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

8.6

Independent relationship 

Client’s relationship with BioFocus is that of an independent contractor, and nothing in this agreement or any Schedule of Work should be construed to create a partnership, joint venture or employer-employee relationship. Neither Party is permitted to act or describe itself as the agent of the other, nor make or represent that it has authority to make any commitments on the other's behalf.

8.7

Interpretation

In this agreement:

8.7.1

the headings are used for convenience only and do not affect any interpretation; and

8.7.2

references to “person(s)” include incorporated and unincorporated persons; references to the singular include the plural and vice versa; and references to the masculine include the feminine; and

8.7.3

where the word “including” is used, it means “including without limitation”. 

8.8

Notices

8.8.1

Any notice to be given under this agreement or any Schedule of Work is to be in writing and sent by registered mail, or by courier, or by fax to the following addresses or to such other address that a Party may notify to the other Party in accordance with this Clause 8.8.

If to Client: Warren C. Lau, President, MetaStat, Inc. 8 Hillside Ave., Suite 207, Montclair, NJ 07042, tel. (970) 744-761

If to BioFocus: Managing Director BioFocus, Chesterford Research Park, Saffron Walden, Essex, CB10 1XL, United Kingdom, tel. +44 1799 533500, fax +44 1799 531495

8.8.2

Notices sent as above are deemed to have been received 3 working days after the day of posting (in the case of inland first class mail), or 7 working days after the date of posting (in the case of air mail), or on the next working day after transmission (in the case of fax messages, but only if a transmission report is generated by the sender's fax machine recording a message from the recipient's fax machine, confirming that the fax was sent to the number indicated above and confirming that all pages were successfully transmitted).

8.9

Law and jurisdiction

The validity, construction and performance of this agreement and each Schedule of Work is governed by the laws of England and Wales and subject to the exclusive jurisdiction of the competent courts in England to which the Parties hereby submit, except that a Party may seek an interim injunction in any court of competent jurisdiction.

8.10 Further action

Each Party agrees to execute, acknowledge and deliver such further instruments, and do all further similar acts, as may be necessary or appropriate to carry out the purposes and intent of this agreement and each Schedule of Work.

8.11 Announcements and press releases 

The Parties agree that:

(i)

1BioFocus and/or its ultimate parent company Galapagos NV shall have the right to make a press release and/or other communications regarding the existence of this agreement with reference to the collaboration between the Parties hereunder, provided that the Client has the opportunity to review such press releases within three (3) working days as of the date it has been submitted to the Client for review; and 

(ii)

the Client shall have the right to make a press release and/or other communications regarding the existence of this agreement with reference to the collaboration between the Parties hereunder, provided that BioFocus and/or Galapagos NV has the opportunity to review such press releases within three (3) working days as of the date it has been submitted to BioFocus or Galapagos NV for review. In addition, BioFocus shall have the right not to be cited in any press release and/or other communication if it so requests.

Page 11 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

8.12 Export

The Parties acknowledge that the export of technical data or materials is subject to the receipt of any necessary export licences by the exporting Party and that the Parties cannot be responsible for any delays attributable to export controls which are beyond the reasonable control of either Party. Each Party agrees not to export or re-export, directly or indirectly, any information, technical data, the direct product of such data, samples, or equipment received or generated under this agreement in violation of any applicable export control laws or governmental regulations.

8.13 Entire agreement

8.13.1

This agreement, in conjunction with individual Schedules of Work entered into under this agreement:

(a)

constitutes the entire and integrated agreement between the Parties with respect to that Schedule of Work; and

 

(b)

supersedes and extinguishes any prior drafts, agreements, undertakings, understandings, promises or conditions, whether oral or written, express or implied between the Parties relating to such subject matter.

8.13.2

Each Party acknowledges to the other that it has not been induced to enter into this agreement nor has it relied upon any representation, promise, assurance, warranty or undertaking (whether in writing or not) by or on behalf of the other Party or any other person save for those contained in this agreement. Accordingly, each of the Parties acknowledges that the only remedy available to it in respect of the subject matter of this agreement and any Schedule of Work is for breach of contract under the terms of this agreement and those of the relevant Schedule of Work and it shall have no right of action against any other Party in respect of any such representations, promise, assurance, warranty or undertaking.

8.13.3

This clause does not exclude any liability which either Party would otherwise have to the other or any right which either of them may have to rescind this agreement in respect of any statements made fraudulently by the other prior to the execution of this agreement or any rights which either of them may have in respect of fraudulent concealment by the other.

8.13.4

If there is any conflict between the terms of a particular Schedule of Work and the terms of this agreement, the terms of this agreement prevail, except in the event and to the extent a deviation to this agreement is explicitly made in the relevant Schedule of Work. In such event, such deviation is only be valid for the applicable Schedule of Work. 

8.14 Counterparts

This agreement and each Schedule of Work may be executed in any number of counterparts, each of which, when executed, shall be an original, and all counterparts together shall constitute one and the same instrument.

AGREED by the Parties through their authorised signatories and executed in two originals, 

			
	For and on behalf of 

Diabesity Inc

	 
	For and on behalf of

BioFocus DPI Limited 

	

Signed: /s/ Warren C. Lau

	 
	

Signed: /s/ Kate Hilyard

	Name: Warren C. Lau

	 
	Name: Kate Hilyard

	Title: President & CEO

	 
	Title: Managing Director, BioFocus

	Date: July 15, 2014

	 
	Date: July 8, 2014

Page 12 of 13

v 3 Nov 2011

Confidential to Diabesity Inc. and BioFocus

SCHEDULE 1:

Template Schedule of Work or Schedule of Work No 1 (as applicable)

Page 13 of 13

v 3 Nov 2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]